POPULARITY
4 episodes with abpi
31 episodes with abpi
3 episodes with abpi
2 episodes with abpi
2 episodes with abpi
The ABPI has recently published guidance on congresses. What does the Code already say on this topic? What does the Guidance include? And what does it all mean. Code Clarity is hosting a webinar on this topic on 6th May 2025, 12.30-1.30pm. Contact us at hello@codeclarity.co.uk for more details.
Dans ce nouvel épisode d'En Tendon, le podcast des kinés, nous accueillons Olivia Ferrand, ostéopathe spécialisée dans les troubles vasculaires ! Cet échange est divisé en deux épisodes ! Voici les sujets abordés dans ce premier épisode : 00:00 - introduction 01:39 - Présentation d'Olivia Ferrand 03:54 - Pourquoi est-ce important de se former dans le triage neuro-vasculaire ? 05:18 - La problématique du « gender gap » dans la recherche scientifique 08:36 - Qu'est-ce que les connaissances neuro-vasculaire apportent comme plus-value dans notre pratique ? 12:05 - L'association étonnante entre l'arthrose et la HTA 14:09 - L'accès direct en kiné, l'avons-nous malgré nous ? 18:53 - Pourquoi Olivia s'est intéressée aux troubles vasculaires initialement ? 21:42 - Quels signes et symptômes devraient nous orienter vers un possible trouble vasculaire ? 22:31 - Un cas clinique hallucinant 24:11 - Que signifie le terme ABPI ? 25:31 - La particularité du triage vasculaire 26:48 - Un autre signal d'alerte crucial à connaître 27:40 - Comment différencier une périostite d'un syndrome des loges d'effort ? 31:49 - Faut-il prendre la tension de tous les patients ? 34:15 - Encore quelques signes vasculaires à connaître… 39 : 32 - Trop d'activité physique est-il délétère pour le système cardio-vasculaire ? 40:31 - Qui sont les tueurs silencieux vasculaires, et pourquoi ? 44:24 - Est-il possible de suspecter un anévrisme au cabinet ? PRÉCISIONS IMPORTANTES : Olivia souhaitait revenir sur certaines affirmations qui lui semblaient imprécises dans le podcast, les voici : - Un signal d'alarme crucial à repérer et non cité dans le podcast est la claudication intermittente/douleur à l'effort ! - Le bilan cardiologique est recommandé à 40 ans et non 30 ans, sauf si prédispositions et/ou raisons particulières ! __________Et comme d'habitude, si tu as aimé ce podcast, le meilleur moyen pour nous le faire savoir c'est de noter cet épisode et/ou de partager le podcast autour de toi, car c'est grâce à toi qu'En tendon grandit chaque jour, donc merci pour ton écoute et ton soutien, c'est essentiel pour nous ! _________________ BONUS : Accédez à des milliers de ressources et outils utiles pour votre pratique clinique en kinésithérapie sur https://www.fullphysio.com/ Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.
In this episode, Nicole McGlennon, Managing Director of Health Innovation East Midlands, is joined by Dr Amit Aggarwal, Executive Director of Medical Affairs and Strategic Partnerships at the Association of the British Pharmaceutical Industry (ABPI). Dr Amit shares more about the ABPI's mission to make the UK the best place to research, develop and use the medicines of the future and explains the importance of the pharmaceutical industry to the UK and its economic benefit The discussion shares examples of collaborative working across the innovation ecosystem and the barriers to adopting innovation. It also covers a new piece of guidance which the ABPI has launched, in partnership with NHS Confederation, on how to develop effective industry partnerships - a practical how-to guide both for companies and NHS organisations about how you can set up a partnership. You can find the guidance here.
As we approach the end of Pride month, Jade explores how the pharmaceutical industry can best support staff and patients who identify as part of the LGBTQ+ community. She talks with Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology, J&J, who shares his personal views on how the industry can improve health outcomes and encourage authenticity. In this interview, they discuss how both the pharmaceutical and healthcare industries can do their best to support people from the LGBTQ+ community, the unique challenges that patients and staff may face and more. A little more on GOLD's guest… Edmond has been with J&J for just over ten years, starting in pharmacovigilance before moving into medical affairs. During this time, he has worked in the areas of diabetes and immunology before recently settling into his current area of expertise, haemato-oncology. Edmond also works as an ABPI final signatory and holds a PhD in Medical Research in Therapeutic Antibodies as well as a Masters in Medical Statistics. He also has 12 years' experience in clinical practice. At the heart of all these academic and professional achievements, Ed is also a proud member of the LGBTQ+ community and strives to be a role model for other members.
What challenges and opportunities await US-based CME providers looking to expand into Europe? As a CME provider, understanding Europe's accreditation landscape and cultural nuances is crucial for successfully delivering education to international audiences. In today's episode of Write Medicine, Susan Yarbrough joins me in dissecting the complexities of CME in Europe and guiding us through the accreditation mosaic. We'll explore key considerations and strategies for navigating European CME, including the need for a strong dose of cultural humility. In episode 107, you'll: 1. Gain insights into the differences between US and European CME accreditation systems 2. Learn practical advice for partnering with local organizations to deliver relevant education 3. Discover the importance of cultural humility and adaptability when expanding CME offerings internationally Tune in now to equip yourself with the knowledge and strategies needed to expand your CME programs confidently into Europe and beyond! Takeaways While European CME accreditation differs significantly from the US, focusing on approving activities rather than providers, the accreditation landscape in Europe is evolving, with a slow but steady movement towards alignment and reciprocity. Reciprocal agreements allow for the exchange of CME credits, but disparities in accepting and using CPD credits across jurisdictions remain a concern. As a US-based CME provider, if you want to expand your offerings to Europe and beyond, as a first step, research the accreditation requirements and cultural nuances of your target European countries or regions. Education providers who want to successfully deliver CME in Europe must cultivate cultural humility as a key ingredient. As a US-based provider, you'll need to understand local guidelines, perform a gap analysis and needs assessment, and have a local footprint to effectively deliver education that is appropriately accredited and tailored to the European audience. Connect with Susan Email: CENerd4Hire@gmail.com Instagram Abbreviations EACCME: European Accreditation Council for Continuing Medical Education ( ECMEC®: The American Medical Association (AMA) has an agreement to mutually recognize continuing medical education (CME) credit with the European Union of Medical Specialties (UEMS). Physicians (MDs, DOs, or equivalent international degree holders) may apply to the AMA to have their EACCME European CME Credits (ECMEC®s) converted to AMA PRA Category 1 Credit™. Resources Ghidinellli M, Pozniak E, Kolanko C, Wilson S. The ongoing challenges faced by providers of CME-CPD in Europe. J CME. 2023;12(1) Timestamps 00:00 Introduction 02:44 Introducing Susan 03:50 Some of the key challenges she sees in accreditation domestically 05:26 Updated guidelines for virtual credit in EACME 3.0 10:03 Differences and similarities between European and US accreditation 12:30 Impact of territoriality on CME content 15:51 Uniformity or standardization for reciprocal agreements in CME accreditation 17:13 Independence in Europe versus the US 21:48 Why the ABPI is attached to having control over content 24:26 How US education providers go about addressing specific needs and gaps in Europe 28:35 What tactical changes may look like to be an effective educator 31:03 Winners and losers in European accreditation 33:34 The extent of international and global CME and how is that going to change 36:03 Susan's practical advice for CME providers 37:50 Key takeaways from today's episode Subscribe to the Write Medicine podcast! Don't forget to subscribe to the Write Medicine podcast for more valuable insights on continuing medical education content for health professionals. Click the Follow button and subscribe on your favorite platform.
In this eye-opening episode, we delve into the complex world of advertising regulations for prescription-only medicines and the challenges faced by online pharmacies, telehealth providers, and healthcare marketers. Louis is joined by our guest, James Walmsley, Managing Director of AdverCheck, shares his expertise on: The regulatory landscape and the roles of the MHRA, PAGB, ABPI, and ASA in overseeing advertising practices The grey areas in current guidance and how they may be confusing for some online companies The potential risks to patient safety when consultations become more like e-commerce transactions The impact of these practices on consumer healthcare companies and the future of prescription-to-OTC switches James also discusses the importance of striking a balance between improving access to healthcare and maintaining compliant and safe practices, and offers advice for pharmacies and pharmacists navigating this complex landscape. Whether you're a healthcare professional, marketer, or simply interested in the future of online healthcare, this episode is a must-listen.
Rina & Jean discuss some myths (please let us know if you think of others). We will be putting these to Alex Fell (Director, PMCPA) at our Annual Conference.
Some key publications from Prof Julie Green: Green. 02-05-2020. 'COVID-19 and district and community nursing.'. British Journal of Community Nursing. DOI > view in repository > Green. 28-11-2019. 'Evaluating the impact of a coaching pilot on students and staff'. British Journal of Nursing. DOI > view in repository > Green. 11-10-2019. 'Challenges to concordance: theories that explain variations in patient responses.'. British Journal of Community Nursing. DOI > view in repository > Green, Julie; Boast, Gillian; Chambers, Ruth; Calderwood, Robin. 09-09-2019. 'Comparison of manual and automated ABPI recording in patients'. . view in repository > Green, Julie; Corcoran, Patsy; Green, Laura; Read, Sue. 19-09-2018. 'A new quality of life wound checklist: the patient voice in wound care'. Wounds UK. view in repository > Green. 31-08-2018. 'Collected Stories: Being cared for at home'. Journal of Academic Development and Education. DOI > view in repository > Gilchrist; Green. 12-06-2018. 'Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis.'. Cochrane Database of Systematic Reviews. DOI > view in repository > Green. 02-06-2018. 'What a great opportunity'. British Journal of Community Nursing. DOI > view in repository > Russell, David; Atkin, Leanne; Betts, April; Dowsett, Caroline; Fatoye, Francis; Gardner, Sarah; Green, Julie; Manu, Chris; McKenzie, Tracey; Meally, Helena; Mitchell, Louise; Mullings, Julie; Odeyemi, Isaac; Sharpe, Andrew; Yeowell, Gillian; Devlin, Nancy. 02-03-2018. 'Using a modified Delphi methodology to gain consensus on the use of dressings in chronic wounds management'. Journal of Wound Care. DOI > view in repository > Green. 02-11-2017. 'What's in a name? Is district nursing in danger of extinction?'. British Journal of Community Nursing. DOI > view in repository > Green. 01-01-2015. 'The challenge of multimorbidity in nurse education: an international perspective.'. Nurse Education Today. DOI > view in repository > Leese, D.; Smithies, L.; Green, Julie. 14-03-2014. 'Recovery-focused practice in mental health'. Nursing Times. view in repository > Gibson, S.; Green, J.. 01-05-2013. 'Review of patients' experiences with fungating wounds and associated quality of life'. Journal of Wound Care. DOI > view in repository >
Hey Team and welcome back to the Can I Have Another Snack? podcast. We've been on hiatus but we're back with a new fortnightly pod. Today I'm talking to Dr. Asher Larmie, AKA The Fat Doctor. Asher is a transgender, non-binary GP who uses they/them pronouns. They are a fat activist and founder of the #NoWeigh campaign. Asher joined me on the Don't Salt My Game Podcast back in May last year, and we had such a great conversation that I just had to have them back for the CIHAS pod.This episode is in response to the news that the NHS/NICE in the UK are contemplating offering weight-loss injectables to kids. These drugs have already been approved in the US (which I discuss here) - it was only a matter of time before we started talking about it here too. In this episode, we talk about the evidence behind semaglutide, or lack thereof, potential side effects and unintended consequences, and of course, we talk about the company behind this drug, Novo Nordisk, who are set to make bank off of fat kids. So yeah, the first episode back is kind of a bummer - but I wanted to make sure we had a good grasp of the science before the media shitstorm kicks off. We also have a new podcast editor - the lovely from - welcome Lucy! (see if you can find the Avery Easter eggs she planted in the new episode format).Can I Have Another Snack? is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.Find out more about Asher's work here.Follow their work on Instagram here and Twitter here. Listen to The Fat Doctor Podcast here.Follow Laura on Instagram here.Subscribe to my newsletter here.Sign up to my upcoming webinar with - ‘Substack for Nutrition Professionals: Launching & Growing Your Email Newsletter'. Here's the transcript in full:Asher Larmie: We had 180 teenagers for a year, and that's it. It's not enough time to understand what is going to happen to that teenager long term. We need studies that have looked back after 20 years. We need to know what's gonna happen to these kids when they become adults, when they become older adults, but not the first year. It's so dangerous. These drugs haven't existed for long enough. We've never used them in children before. It's terrifying to me. Absolutely terrifying.Laura Thomas: Hey, welcome to the Can I Have Another Snack? podcast where we talk about food, bodies and identity, especially through the lens of parenting. I'm Laura Thomas. I'm an anti-diet registered nutritionist, and I also write the Can I Have Another Snack? newsletter. Today I'm talking to Dr. Asher Larmie. Asher, who uses they/them pronouns, is a transgender non-binary GP and fat activist who is campaigning for an end to medical weight stigma.They're the founder of the #NoWeigh campaign and they have over 20 years of medical experience and have been fat for even longer than thatLaura Thomas: As the self-styled Fat Doctor, Asher started a blog in June 2020. They now also host a successful podcast and run a number of training courses, as well as monthly webinars for people who are interested in learning about weight inclusivity.Today I'm gonna be talking to Asher about the news that came out of the UK that the National Institute for Clinical Excellence, or NICE, is considering approving the weight loss injectable Semaglutide for kids. Asher is here to explain to us why this is catastrophic for kids' sense of safety in their bodies and their wellbeing.We talk about the evidence behind Semaglutide, or I suppose the lack thereof, the potential side effects and unintended consequences. And of course, we talk about the company behind this drug, Novo Nordisk, who are set to make bank off of fat kids.Just before we get to Asher though, I wanna tell you real quick about the benefits of becoming a paid subscriber to the, Can I Have Another Snack newsletter community, whole universe.Now, I know we're not used to having to pay for content on the internet, and why would you pay for something where 85% of the content is free? Well, that's a great question. I'd love to answer it for you. Well, because without paying supporters, this work just wouldn't be possible. As well as supporting me in the time it takes to research, interview contributors and write articles, your support goes towards paying guests for their time and their labour, as well as a podcast and newsletter editor. You also help keep this space ad and sponsor free so I don't have to sell out to advertisers or exploit my kid for freebies. Plus keeping the community closed to paying subscribers only means that we keep the trolls and the fatphobes out.I recently asked the CIHAS community why they support the newsletter, and this is what they had to say: “I am a mum of one, fairly adventurous, self-proclaimed vegetarian and one theoretical omnivore. The latter survives almost exclusively on added sugar and butter, but mostly sugar. I consumed all the picky eating advice, some of it really well-meaning, and pretty mellow. But by seven years in, I was more frustrated, confused, and full of self-doubt than ever. Enter CIHAS. The no-nonsense, cut through the bullshit, science-backed content is exceptional. The content about sugar is especially helpful to me, and the anti diet lens is an anecdote to my extremely anti-fat slash diet-culture conditioning. And as an American, the British references are just an added bonus to say your work is actively changing. My life is not an understatement. Thank you.” Well, thank you to the reader who shared that lovely testimonial, and if that hasn't inspired you to become a paid subscriber, I don't know what will. It's just a fiver a month or £50 for the entire year, and you get loads of cool perks, as well as just my undying gratitude for supporting my work. Head to laurathomas.substack.com to subscribe now. All right, team. Over to Asher. Laura Thomas: So Asher, last month, the news broke that the Department of Health have recently asked the Medical Watchdog NICE. Which stands for the National Institute of Clinical Excellence to review the so-called benefits of using weight loss injectables for kids aged between 12 and 17 years old. Specifically, they're looking at the drug Semaglutide. Which has been in the news a lot recently, which I'm sure we'll get to. But I wondered if we could start by talking about what exactly Semaglutide is, how it works and what the evidence says about it. Asher Larmie: You sort of put it in air quotations, or you said so-called benefits, didn't you? I like that, yeah. Cause that, that was a really good way to start. Yeah. So Semaglutide, it's a incretin mimetic. It mimics a hormone called inncretin or one of the hormones, GLP1, which is an incretin, and, and these hormones are released by the gut in everybody's body and in response to eating. So look, you have a meal, your gut releases these hormones and they impact several parts of the body. The main thing they do is they impact the insulin pathway. So they impact the pancreas, but they also have various other effects. And one of them is they sort of decrease appetite and increase a feeling of satiety, of fullness, which makes sense, right? Because when you start eating, after a while, your body sort of wants to tell you, okay, you've been eating now like it's time to stop eating cos you can't eat forever. And when we talk about intuitive eating, we're always talking about, like, picking up our hunger cues and picking up our fullness cues. Well, there's a reason we have hunger cues and fullness cues. It's nothing to do with the size of your stomach or anything like that. It's because of these hormones acting on the appetite sensors in the brain. So this drug Semaglutide was designed for diabetics because of the way that it works on the pancreas and the insulin pathway. But they found very quickly that it causes suppression. And so people were losing weight on this drug. Their diabetics were losing weight.Laura Thomas: And to this point, just to clarify, you are talking about in adults, right?Asher Larmie: Absolutely. Laura Thomas: This research was initially done in diabetic adults?Asher Larmie: In diabetic adults. And we're talking…when they probably started working on this drug, this would've been early 2000s, I think the first one of its…the first drug in this group - and it wasn't Semaglutide, by the way, it was a completely different drug - would've come out in the sort of early 2000s. Semaglutide for diabetics, which is Ozempic, Ozempic is the brand name for the drug. Semaglutide one milligram weekly subcutaneous injection. So it comes like a little pen and you inject it into your stomach, usually. One milligram is the maximum dose for diabetics and the brand is Ozempic. I can't remember, I don't wanna say for sure, but it was definitely after 2010, somewhere around that time that we started using it in diabetics or it was approved, and more recently we've been using it in diabetics more and more and more. It's a very expensive drug, it's the most expensive diabetic drug…I dunno how it compares to insulin, but certainly compared to all the other diabetic drugs.Laura Thomas: Yeah, I saw that for like a month's supply of Wegovy, which is the, the weight loss version of Ozempic, that it costs something like $1,300 a month in the US. I don't know what it is in the UK, but in the US, $1,300 a month, that is an astounding amount of money.Asher Larmie: Sure. And that's the private prescription. But when you look in the NHS, it's how much it costs the NHS per month, right? So that's always like then.. sale price, it's, you know, it's…Laura Thomas: That's the wholesale. Asher Larmie: The wholesale, the Costco price. Laura Thomas: The Costco price! Asher Larmie: And I can't remember what it is, but it's at least twice as much. Laura Thomas: It's expensive. Asher Larmie: It's expensive. Compared to Metformin, which is probably like £1 a month. You know, in terms of diabetic drugs, it's much more expensive. Anyway, so Novo Nordisk creates Semaglutide. It's a once weekly injection. Ozempic, people like it. And then, quickly they realized it was kind of like the Viagra story. I mean, if you know the story of Viagra, Sildenafil was supposed to be for blood pressure, was anti-hypertensive for blood pressure. But they soon realised it's not so much what it does to blood pressure - in fact, it wasn't very good with blood pressure. But look at the side effects. You think something was happening to men. And so they realised, well, we could definitely corner the market here because there's no other sort of medicine that has quite the same effects. And so Viagra was born. This is very similar. Ozempic was being used on diabetics. Diabetics were losing weight, and they thought, right, let's push this through. Let's, let's turn this into a weight loss drug. And so they started studies in 2017, 2018, they started the actual study. The results came out late 2020, maybe early 2021, depending on the studies. There's been eight. And then the teenage one, so we're talking still adults only. Right. Literally within like six months, the FDA had approved it and NICE took a little bit longer. They sort of semi approved it in 2022 and fully approved it in 2023. With very, very little data. All we know is that this drug suppresses your appetite and therefore makes you lose weight. And it also does all the other things, like sort of acts on the insulin pathway and all the other things that it's known to do, but we have no idea how that impacts non-diabetics and how that will impact children, certainly. We have a zero idea. Laura Thomas: Okay, so just to summarise, cuz you're a doctor. And not everybody else is! This drug is a GLP1 analog. So it mimics a hormone in the gut that is produced naturally in response to, in response to eating a meal. Our bodies, our guts pump out this hormone. And that is one of the ways, one of the pathways, one of the signals that tells our brain, okay, we can slow down now. We've, we've got enough here, we'll be good for a little while. Right. Asher Larmie: That's it. Laura Thomas: And so we have a fall in our appetite basically. What this drug is doing, it's an external version of that hormone that you are injecting into your stomach, that artificially suppresses your appetite. Right. Asher Larmie: That's it. Laura Thomas: So it's not…it's essentially tricking your body into thinking that you've had more food than you actually have. Now this might be helpful when you have a chronic condition such as Type 2 Diabetes, it might help manage blood glucose. However, what you're saying is that we don't know what the impacts are on people who have just been prescribed this for weight loss. And we also don't know the impact of this on children who are growing.Asher Larmie: Mm-hmm. Laura Thomas: Which is…I mean, all of it is a mess. All of it is concerning and upsetting to me, but it feels particularly upsetting and concerning to me when we're talking about children, when we don't know the full scale of the impact. So what evidence do we have on children? You know, why are we at a…I mean, this is a separate conversation, but if we could get into the minds of the DoH and the NICE people, why do they think that we should start prescribing this to children? Asher Larmie: Well, first of all, we've been lied to about this drug, although I think the Department of Health and the National Institute of Clinical Excellence should be smart enough to figure out that they've been lied to about this drug. I can understand why the average person doesn't, but if you've read studies, which I have in detail, all eight of them, well, seven of them, one wasn't published, and the one on teens, it's very obvious. Because the first thing is, in order for them to achieve weight loss, the participants in this trial had to go on a diet 500 calories deficit, plus exercising for 150 minutes a week, plus an hour of counselling every month. Laura Thomas: Right, We don't know if the impact is coming from the diet and lifestyle modifications versus the drug in and of itself.Asher Larmie: We do to a degree because everybody was on the diet. Only some people were on the Wegovy. And others were on placebo, just a water injection. And so what we saw was a) that diets don't work. Which you've been saying this whole time! The diet-only group only lost about 2.5% of their body weights over a period of a year, and then regained it all. So diets don't work. What a surprise. The people who took the Wegovy definitely lost much more weight. There was a significant difference. So in the first 16 weeks, that's when you lose the most amount of weight. We know this. This is the physiological response to calorie deficits or energy deficits. It then slows down and between sort of week 16, week 20 until about month 10, it sort of slowed down, but was still going. And then at month 10 in the first study, we reached the nadir, which is the peak, and then people started regaining weight. If you look at the study over two years, people regained something like 15% of the weight that they lost within eight months. You carry that forwards….I mean, it's not particularly scientific to carry it forwards, but if you were to assume that every eight months you'd gain about 15% of the weight that you'd lost. Within five years, you've regained the weight. And that's if you are on the medication. If you stop the medication, which in the UK you only are entitled to have it for two years, the moment you stop that medication, you will start regaining the weight.There is absolutely no way you can maintain it because nobody could. Nobody could maintain it, even when they stayed on the diet. They could not maintain that weight loss. They immediately start gaining the weight back and at a rate that is almost unprecedented. We've never seen such dramatic weight loss followed by weight regain with any other weight loss drug.Laura Thomas: Well, shit, you're gonna be hungry! As soon as you stop taking that drug, like, you're gonna be fucking hungry!Asher Larmie: Sure. Although I think it's more than that. Like I don't even think that explains it. There's something else that's happening in the body and we just don't know what it is, right, to know how it's workingLaura Thomas: And this is it, like, when you go in and you start messing with hormone pathways. It's not just gonna be one individual pathway in isolation, there are gonna be knock on effects and that is what we've seen in historic weight loss medications, right? We're, we're giving people something for weight loss, but it turns out, oh, actually we're burning them alive from the inside. Right? That's what has happened with other, with other drugs…or where we've, we've tried to suppress people's appetites, but we've also suppressed their libido because again, you can't isolate out individual pathways within the human body cos everything is interconnected.Asher Larmie: That's exactly right. And actually what we know is that this drug primarily works on the insulin pathway. And the insulin pathway is extremely important for so many different reasons. We know that the insulin pathway, insulin sensitivity, insulin resistance, for example, leads to weight gains. So we could, you know, make an argument that actually once you stop messing with the insulin pathway, perhaps there is a weight regain and perhaps you are making permanent changes to the body because you are messing with the pathway you shouldn't be messing with.I, you know, I often say don't play about with a healthy organ if you can avoid it. And so in a diabetic, the pancreas is already exhausted. The pancreas is already struggling, so okay, you're gonna mess with pancreas, but it needs help anyway. Benefits outweigh the risks, but in this case, this people with a healthy pancreas, especially children, The last thing you wanna do is mess with organs that are still growing. You know that that's massively worrying. So the first thing I will say is that we have been lied to about this medication. We have been told that this medication will help you to lose weight and keep it off. Wrong. Even NICE said with the adults' guidelines, you will not be able to maintain the weight loss.So that's one thing…Laura Thomas: And can I ask you…sorry, cos I know you're like desperate to tell me your second point! But I'm just curious, like, what is the reason that NICE are giving for people only being able to stay on the drug for two years? Asher Larmie: Because that's all the evidence we have. We don't have anything beyond two years. If we had evidence for five years, they probably would've said five, but they've said, look, all you've got is two years, so that's all we can allow. Now, remember with NICE, it's the UK, this is a Nationalised Health Services, there's only a certain amount of money, so when NICE is approving a drug, they're not just worried about the drug safety, efficacy, you know, and all of that stuff. They're also worried about…is this a cost effective…yeah, it's money. Is it cost effective? So Novo Nordisk had to prove to NICE that there was a cost benefit. So helping people lose weight for two years and then regain it, which they admitted would happen because that's what their studies show. And so that's the problem if you look into that calculation, that calculation is materially flawed. The fact that NICE accepted it makes me very sceptical of the whole thing, but we can cross that bridge later. The point is that in the UK you can only have it for two years. But even if you continued it for five years, you will have regained most of the weight back by that point in time. And then they talk about maintenance doses. What maintenance dose? If the treatment dose doesn't work, then what's the maintenance dose gonna do? What does that say to me? They can only keep going up, up and up, right? At what point in time are we gonna accept that we really shouldn't be messing around with the body like that? Just for temporary weight loss. That's all it's doing. It's not improving your health. There's no evidence that it does anything for your health. It just makes you lose weight. They didn't even bother to measure the impact on your health, even your like, blood pressure, blood sugar, cholesterol. They didn't even bother to do like a statistical analysis of that, I think because they knew that they wouldn't be able to find anything. Laura Thomas: It's just so transparent, isn't it? When you say that? Like it's just, we don't actually give a shit about your health. We don't care about any other parameter of your wellbeing. We just wanna make money off of you.Asher Larmie: And so you asked, you said, well, why? Why are we trying to get this available for children? And the answer is simple: for more money. Novo Nordisk is a, you know, a traded company. They have a, a group of shareholders and they're constantly trying to improve their, you know, profit margin.And, and the thing is, when you look at all of the, if the last 15 years or so, there's been this huge push, hasn't there to -quote unquote- tackle the -quote unquote- ob*sity epidemic. And, you know, we have a -quote unquote- war on ob*sity and all these, you know, like really kind of like highly charged words.Novo Nordisk has had their hands in all of this. Novo Nordisk has fingerprints on every single article that you read in the paper. Every single PR campaign for the last 10 years. Whenever you hear the word childhood ob*sity in the, in the papers…whenever you hear that word, if you look carefully enough, you will find Novo Nordisk.They have wanted to sell this drug to teenagers for a really long time. So much so that the American Academy of Pediatrics, when they brought out their guidelines, they actually held off and waited for Novo Nordisk to be able to put their study into the, into the guidelines. Literally they were like, this is the cutoff date. And then they went, oh, hang on, hang on, hang on. Novo's not ready. Alright, let's just wait. Let's just wait. Let's just wait. Novo's ready now. Okay. We can proceed. That's how much influence Novo Nordisk has. And so it's simply about making money. The risk, the potential risk to children is really mind boggling.Laura Thomas: Yeah. So let's talk about this because there's, as far as I know, there's one study in adolescence. Is that right? Asher Larmie: That's it, yeah. Laura Thomas: Should we talk about that single study that they are basing this recommendation or this, you know, it hasn't gone through yet, but this, I mean, I mean, come on. The writing is on the wall, right. They're gonna do everything that they can to push this through. Asher Larmie: They will. Laura Thomas: First of all, let's talk about the study, and then let's talk about the implication for children, for adolescentsAsher Larmie: 180 12-17 year olds are involved in the study. There's only 180. Bearing in mind that the one for adults, the first one was 2000. 180 is actually a very low number of people. And basically it was your typical randomised controlled trials. Some got placebo, some got Wegovy. You know, they did it for 68 weeks. And then they were interested in change in body mass index. That's all they were interested in. They didn't look at anything else, and they found exactly what all of the other studies found: that in the first year, children lost weight and they lost much more when they took this drug than they did when they had placebo, just water.It's not surprising. That is what always happens. You know, when you have a drug that's going to suppress appetite, it's going to be more effective than just, you know, trying to suppress your own appetite, if that makes sense. Right. So of course it was effective, but it was only effective for the first year. That's all we've got and that's all the data. We had 180 teenagers for a year, and that's it. It's not enough time to understand what is going to happen to that teenager long term. We need studies that have looked back after 20 years. We need to know what's gonna happen to these kids when they become adults, when they become older adults, but not the first year. It's so dangerous. These drugs haven't existed for long enough. We've never used them in children before. It's terrifying to me. Absolutely terrifying.Laura Thomas: Something that I found really interesting…so shout out to Reagan Chastain, who did a really great deep dive on this, on her, Weight and Healthcare Substack, I'll link to it. But one of the things that, that she pointed out were all of the side effects that were reported in this study. A lot of them were related to gastrointestinal side effects, so a lot of nausea, vomiting, diarrhoea and abdominal pain. And so again, of course if you've got a kid who is nauseous, who has diarrhoea, if they've got that for an entire year, they're going to lose weight. But at what cost to that child? To their quality of life? To like think about if you feel sick, like even for a couple of hours during the day, let alone for an entire year. And these are kids who are presumably going to school, trying to learn, trying to have a social life, trying to navigate the headfuck that is puberty, right? All of that stuff. And we think it's a good idea to subject them to this kind of…like for why? Why?Asher Larmie: Yeah. So for me, weight loss and children is absolutely unacceptable. Always. Okay. If I see a child who is accidentally losing weight…Laura Thomas: Huge red flag, huge red flag.Asher Larmie: Massive red flag like that, that's like panic stations. Figure it out immediately. The second thing that I will say about children is that we know that dieting of any kind is going to predispose them to eating disorders, especially at that stage in life, especially at this…Laura Thomas: It is the most vulnerable point in a child's development... Asher Larmie: Absolutely. Laura Thomas: For, yeah. Yeah. The onset of an eating disorder.Asher Larmie: And we know that the more extreme their sort of dieting behaviour is, the more likely they are to develop an eating disorder. So that's the second thing. It's not just that dieting creates eating, but the more extreme…now, taking drugs is one of the most extreme form of dieting out there.So what we are doing is we are essentially prescribing eating disorders to adolescents. It is no wonder that over the last 20 years, certainly over the last few years, where we've become more and more obsessed with weight in children, where we keep sending them to these -quote unquote- weight management clinics, and we keep singling them out at school and policing what they eat and all this stuff. If you're a fat kid nowadays, like, you know, you can't even bring in a packet of crisps in your lunchbox without getting told off by your teachers. Laura Thomas: You can't even have a snack that's over a hundred calories. It's something I'm writing about at the moment and it's fucking horrendous, because we're literally policing the amount of food that a child, a growing child can have.Asher Larmie: Yeah, it's despicable. But what are we doing? More importantly, we are literally prescribing an eating disorder to them. We are saying to them, this is what's gonna happen. And are we surprised that nowadays eating disorder rates have gone up dramatically? Laura Thomas: Escalated. Asher Larmie: They're escalating in boys, they're escalating in people with like, you know, multiple marginalised identities. You know, it's not just a really thin, sort of, like, fragile teenage girl anymore that we need to be worried about. We have to be really concerned about all of these young. boys, for example, who were trying to build up muscle. It's actually quite terrifying what's happening to young people.Their mental health is really poor anyway at the moment, and what we're adding to, with this weight management, is just awful. So this isn't even about the drug. This is just about the fact that you should never mess with weights in a child. You should never, ever mess with growing organs, just let the child grow up.Laura Thomas: I wanted to ask you about, like, what are the implications of putting a child on a calorie restricted diet? Messing with their energy intake while they are growing and developing, like, what are the implications there for…around their physical development, around puberty, around sexual development, all of those things? Do we know or do we just not know?Asher Larmie: I was gonna say, first of all, it's amazing how much we don't know. No one is interested in researching this. No one ever says, what are the risks of putting a child on this medication? You know, they look at the side effects of the medication, but no one's actually said, what happens to children if you put them on diet after diet, after diet when they're young?We know the answer to this question because we are, and we are of the generation. I'm 43 years old. I was on a diet when I was a kid. I know exactly what that did to me. I weight cycled and weight cycled and weight cycled and weight cycled. It messed with me mentally. It messed with my self-esteem, my self-worth, my confidence. Instead of helping me to trust my body, it did the opposite, it took away my relationship with my body, my relationship with food, all of these things, like, it completely messed with that. So that's from a kind of like psychological point of view. But from a, from a physical point of view with these particular drugs, we don't know. We're not just worried about malabsorption. You're not getting enough nutrients if you're not eating enough food. That's, that's hugely problematic. Right? Laura Thomas: Yeah. And I know you, you say we don't know, but I think. We have a good sense, right? Like we can infer. What we would imagine would probably happen, like you say, if, if you don't have enough nutrition, if you have deficiencies. What I'm thinking about in particular is bone health and how can, you know, while you're still trying to achieve peak bone mass? You are then putting people at risk, children at risk for falls and fractures and you know, osteoporosis as they get older.Asher Larmie: Osteoporosis, anemia, you know, all sorts of things. Also gastrointestinal problems. So we are looking at things like, you know, irritable bowel syndrome and stuff that, you know, you, you mess around with the gut cos this drug, like I said…Laura Thomas: That's what you're doing. Asher Larmie: This drug impacts your appetite centres, but it also impacts your gut itself. So you're gonna mess, you know, we're talking sort of gut function and motility issues. And this is the thing that like, you know, most concerns me out of everything is, you are messing with a healthy pancreas. Now if you understand the insulin pathway, what happens with insulin is that when we ate food, sugar, insulin is released because of this incretin, right? The incretin from the gut, the GLP1 comes along, tells the pancreas: Hey, there's food here. Laura Thomas: You need to process it. Asher Larmie: And, and it goes, woo, I'm gonna release lots of insulin. So that's the pancreas and insulin. Insulin is like a key. If you put the key into the lock and you turn the lock that you open the door. Sugar can go from the blood where it's, you know, currently sitting, into the cell, which can then be used as energy for the cell, or can be stored to be used later. So you need the sugar to go from the blood, where it's useless, into the cell, where it's needed and insulin is the key. Now over time some people develop something called insulin resistance. Because you're overproducing insulin, and that's one of the first things that happen is we start overproducing insulin. Nobody knows why. It's probably genetic. You start overproducing insulin. So now there's lots and lots and lots of keys, constantly trying to turn locks and eventually the, the locks become a bit faulty, right? You keep messing around with the locks after a while, locks, you know, stop working as well. So now you can't open the door to get into the cell so there's more sugar in the blood. And eventually when you have enough sugar in the blood, you develop a condition called Diabetes, Type 2 Diabetes. At the same time, because of all this stuff that's happening, the pancreas is panicking. I keep releasing insulin, but there's still loads of sugar in the blood. What's going on? So the pancreas does what, like, you know, like what Jewish mothers do, you know? It's like, let's just keep going. It doesn't stop to think. Mm. I wonder what's going on. No, no, no. Just, let's just keep doing the same thing and let's just… Laura Thomas: It overworks itself.Asher Larmie: Yeah. It becomes exhausted. As any organ would. After a while it becomes knackered. We call it pancreatic exhaustion. At that point in time, you are also going to, it's also gonna have implications and you'll develop Type 2 Diabetes. So here's my thing. This drug is making you secrete lots and lots of insulin. Because like you said, it's fake incretin, so you're injecting it into your skin. All of a sudden you have lots more of this, you know, a mimic of this hormone in your blood at all times. So your body starts producing more and more insulin. Now as it produces more and more insulin. If you're a diabetic, this is great cos you need the insulin. But if you are not a diabetic, you're producing all of this insulin. Keep producing it, keep producing, keep producing. Isn't it possible, theoretically, that you could actually be speeding up the process of insulin resistance? And so what you could be doing is you could be speeding up the process of developing Type 2 Diabetes. So isn't it possible - and it's just the theory cos there's no evidence. But isn't it possible that, if we give a 12 year old this drug and they take it for say, five years, because by that point in time they'll be allowed to take for five years, they've taken it five years and then they start to develop insulin resistance, and maybe by the time they're in their twenties they've got quite profound insulin resistance and then they get diabetes at 26 say, and people think, gosh, diabetes at 26, that's quite young, but you know, they are fat, so it's their fault they've been fat, so they were kids, so it's their fault.This would be…it wouldn't surprise me and we wouldn't be able to do anything about it by then. So I'm not saying that this drug is going to cause diabetes. I'm just saying that it is theoretically possible that it could cause diabetes because excess of insulin is the first step of insulin resistance and diabetes progression.So this is really worrying and nobody is addressing this. It also interferes with the cholesterol pathway and all sorts of other things. So my worry is that it's actually making things worse rather than better. Laura Thomas: And it sounds as though Novo Nordisk are not asking those questions.Asher Larmie: There's no mention of this anywhere in their literature, I have to say. Nobody's asking, and this is what I can't understand. right. I'm a GP. I am not an expert. There must be people out there who understand the process of insulin resistance and they're thinking, Hmm, logically this makes sense. I wonder if we need to look into it. But I never hear anyone talk about it.And I remember the first time. I brought it up with Greg Dodell, who is an endocrinologist. I remember the first time I said, are we not worried about this? And he was like, no, of course not. Because you know it, it reduces insulin resistance. And I was like, no, no, no. It, it reduces insulin resistance in diabetics, but what about in healthy people long term? Shouldn't we be worried about this? And I remember at one point in time Greg going, oh. No one, no one said this before. I was like, why is no one talking about this? But nobody is, and that's just one of my many concerns. It also causes pancreatitis, acute pancreatitis. Which is a life-threatening condition.There's no evidence that causes pancreatic cancer. I just wanna point out, but we also don't have enough long-term data to say whether it does or it doesn't. So that is an absolute, we couldn't say, you know, we couldn't possibly comment. Laura Thomas: Even, you know, regardless of what the long term implications are, which..obviously there is not enough research going on to establish that, but even the short term impacts on children, you know, again, some of those side effects that were reported in the study we were talking about were gallbladder problems, gallstones, low blood pressure, itching, rash, like all kinds of side effects on top of the nausea, vomiting, diarrhoea, headache, abdominal pain, all these other things. And I just… there is no rationale that I think you could convince me of where that is a good idea, to subject children to that. And you know, and that's without knowing the answers to…what about their growth? What impact is this gonna have on their development? Without knowing any of that. Asher Larmie: When we are making a recommendation, right, there's two things we look at. Number one is the quality of the evidence. The quality of the evidence here is shit. The second thing we have to understand is, are the benefits, do the benefits far outweigh the risks?If the benefits don't outweigh the risks, or if the benefits are sort of similar to the risks then we shouldn't be recommending this, this, any medication. Not only is the evidence shit, but there are no proven benefits apart from temporary weight loss. And there are so many risks. Some of them hypothetical, but as you say, some of them very real and very immediate.So if that's the case, there is never a reason to give this drug to a child, never, ever, ever, especially because, yes, they are able to consent, but only if they're given all of the information and aren't being pressured into it by external, external people and, and unfortunately they just won't have that ability. They won't have the agency over their body to say, no, I know I'm fat, but I'm not taking this medication. Most of them won't feel that way. So no, I don't think…we have a consent issue here. We have all sorts of issues. Laura Thomas: I think it's an important point is that kids are gonna feel pressured into it, both from medical anti-fat bias, as well as just anti-fat bias that is everywhere, that they're gonna feel from their peers, that they're gonna feel from their parents, that they're gonna feel from teachers. Yeah. Like, I can also understand why this drug is so attractive to so many people if it reduces the stigma that they're experiencing. Even if it is temporary and even if it has a really high price tag associated with it.Speaking of price tags, The Guardian reported earlier this month that Novo Nordisk, so the company that makes Wegovy, paid more than £21.7 million to UK health experts and organisations in just three years, according to Disclosure UK records. And then several of those experts and organizations went on to make submissions to NICE, supporting the drug's approval for use in adults. It just, again, shows you that enormous conflict of interest within Novo Nordisk. But like we said before, the, the writing's kind of on the wall in terms of this getting pushed through NICE. And, you know, being incorporated into NICE guidelines.What does that process look like from here? Like what happens between now and then? And you know, how can we intercept, you know, where do we submit evidence and submit concerns and ask these questions? Can we even do that? Or is this just gonna go through? Asher Larmie: The can we is tricky actually. It's not the kind of process where you can get involved as as easy as you'd like to.Laura Thomas: It's not like a public consultation, basically. Asher Larmie: It's not. What will happen is that NICE has to make a decision about whether they're going to look into it first. And then they will form a guidelines committee. NICE will have a group of…it doesn't have to be doctors. It'll be, uh, experts. And some of them will be more interested in data and some of them will be interested in finances and some of them will be doctors and not necessarily pediatricians or endocrinologists. They could be psychiatrists, they could be anything. And they're just members of the panel. So you get this little guideline committee and then you've got your stakeholders. And so there will be certain groups that will be invited to partake. Obviously Novo Nordisk is gonna be… Laura Thomas: At the table.Asher Larmie: …doing the big presentation. In the adult one we had Ob*sity UK, a charity that is funded by Novo Nordisk. We had another ob*sity charity, whose name I can't quite remember, but again, is funded by Novo Nordisk. We had Professor John Wilding, who is the lead author of the Step 1 trial, the Wegovy Trial who has been paid countless times… Laura Thomas: Handsomely. Asher Larmie: Handsomely by Novo Nordisk. And that was basically it. There was nobody not representing, Novo Nordisk. And so they go through like you know, the beginning and people were asked to submit evidence and then you know, there are questions and then they have to submit more evidence and then they have the draft guidelines.And there is probably a time when you can get involved and register your concerns. But I don't think it's open to the public. I don't believe, to my knowledge, that it's open to the public. I think that if this does happen, we are going to have to consciously, and by we, I mean the kind of people who are, you know, advocating against this drug being used in children are going to have to consciously get together and find a way to get involved in this process.I wasn't with it enough when NICE was looking at Wegovy, it was too early on. It wasn't far enough into my sort of, I guess, deliverance… Laura Thomas: Activism. Asher Larmie: Deliverance, I would say more! From, from diet culture and weight stigma, but certainly this time around we're gonna have to do something about it. It's absolutely unacceptable, but to be honest, I would like it not to get that far.The Guardian, the Observer, have been writing a few political pieces about the politics of Novo Nordisk. And they have in the UK had a bit of a slap on the wrist. I don't think they're taking it very seriously. I don't think they're worried about it, but they have been caught doing some very unethical things. We're not surprised. They are very aggressive in their marketing campaign. And you know the, how much did you say it was? 20 million.Laura Thomas: Yeah, 21.7 million.Asher Larmie: It's nothing compared to how much they spent in America. That was 150 million or something. Like, it's nothing. I'm not going to, for one second defend my colleagues cos I don't have time for that. But I do think a lot of them will have been going to weight management courses, conferences, and conferences, whatever. And not realised that because, because Novo Nordisk was not outspoken. They weren't like, we are Novo Nordisk and we are presenting this data to you. They ran these courses without telling them yeah, that they were running these courses.And so a lot of my colleagues are fanatical about this drug and also, again, most of my colleagues learn a lot of medicine from reading the Sun and the Daily Mail, and maybe not the Sun or the Daily Mail. Maybe my colleagues are too high brow for that. You know? They're far too snobby to read the Sun or the Daily Mail. But they're reading it in the paper. They're reading their stuff in the paper. They're not reading.Laura Thomas: They're reading, like, Henry Dimbleby talk about ultra processed food. Like yeah, he knows what the fuck he's talking about. Asher Larmie: How many, how many fat people have gone to see a doctor and they've been recommended, oh, you should try keto because, you know, that worked for my uncle, or something stupid like that.Like, you know, doctors really have no clue when it comes to nutrition, when it comes to -quote unquote- weight. Um, what do they call it? Laura Thomas: Weight management. Asher Larmie: Weight Management, right? So they just say stuff, they repeat stuff they've read in the papers. So they've all got it in this head that this is a miracle drug because of this beautiful PR campaign.Now, if I worked in public relations, I would be massively impressed. But as a doctor who is conscious of the fact that this drug is going to massively harm children and is already massively harming adults, I am horrified that this is the society that we live in. So we have to do something about this. We really do. But all we can do is educate at the moment, because I don't know how much more political power we have.Laura Thomas: I'm counting on you, basically Asher, to send up the bat signal and when it's time for us to fuck shit up, just let me knowAsher Larmie: We're keeping a close eye. Again, shout out to Reagan. She's amazing and she has been keeping on top of what's happening in the UK, and the politics with no, because obviously, Reagan, I, I learn a lot of, I learned most of my stuff from Reagan, but there are a group of us around the world that are doing whatever we can to, to shed some light on the very dark, underhanded dealings of this company.And because she's keeping abreast of what's happening in the UK, the one good thing I can say about it's the UK is that it's a lot more out in the open. Yes. You know, the FDA, it's all done behind closed doors and there's, there's no legislation, there's no, there's no legal requirements to do things a certain way.But if you've noticed the ABPI, which stands for something to do with pharmaceutical industry and their main organisation, has kicked Novo Nordisk out and given them a really, you know, has given them a telling off because of the ethics, because of what they've done and how unethical it's been.So this is my point. I think we also need to be exposing them for the fraudsters that they are. And anyone and everyone can do that. My friend Jeanette, who is The Mindset Nutritionist, she just wrote a Substack newsletter where there was an article, uh, that was in the papers last week about how, how much fat people are costing the NHS.Laura Thomas: I saw this.. Asher Larmie: Yeah And Jeanette basically is like, she talked about it and at the end she was like, oh, by the way, this person's funded by Novo Nordisk. And it's like, oh, there you go. You can find Novo's name anytime you try and look into it. So, you know, if you're sitting at home thinking, what can I do about this? Feel free to do a little bit of sleuthing, like Googling by yourself and try, just try and find the name, Novo Nordisk. Google the name of the doctor that's quoted in the article, and then Google Novo Nordisk and see where you can find the connections. Cause I think the more we bring attention to this, the, the more we expose these fraudsters for who they are.Laura Thomas: Right? Any investigative journalists listening. You know, hit Asher up. Asher Larmie: Yeah. I'm totally on board. That's it. I'll give you my number.Laura Thomas: What you're saying is that we, we need to kind of make a noise about how unethical and dubious all of this is. And, and how devastating this could be if it, if it goes through, so yes.Okay, well, we'll see how this all plays out. If you haven't signed up to Reagan's newsletter and Jeanette's newsletter, I'll make sure that I've linked to both of those in the show notes so that you, you know, we can watch out for developments. And of course I'll link to Asher's social media and everything so you can, you can follow his work as well.Asher Larmie: I am in the process of bringing out a book about this. So if you're interested in finding out a little bit more, it's a little ebook, everything that we've talked about, but in much more detail. So, yeah, keep your eye out.Laura Thomas: All right, Asher, to wrap up at the end of every episode, we share what we have been snacking on.So it can be an actual, literal snack if you want, or just something that you've been really vibing on, something you're really interested in and you wanna share with the audience, a book, a podcast, whatever. What do you have for us? Asher Larmie: Mine's a book. It's called, It Was Always Ours by Jessica Wilson.Laura Thomas: Oh, yeah. We had Jessica on the podcast talking about her book.Asher Larmie: Oh, oh. Well then I'm not bringing any new revelation. I dunno what she said, but I absolutely love this book.Laura Thomas: You can give it a plug and I'll link, I'll link to the episode as well.Asher Larmie: It's such a good book. It's great. I found it a very easy book to read. You know like sometimes when you read non-fiction books, it feels heavyLaura Thomas: There's so many like pop culture references, that I think it just make it feel really like relatable and understandable. She digs into Goop. That's brilliant. Asher Larmie: And it's funny! Really funny. Really funny. Like it keep, it keeps you laughing until the end.There was like one chapter at the end where she's talking about goop, where I was literally rolling around giggling. It's a really insightful book when it comes to just how anti-fatness has played out, especially within the black community. Cause it's a, it's a book written by a black woman for black people, for black women.But I think there's so much to learn from reading this book, so cannot plug this book enough. Love it, love it, love it, love it, love it. And I think I've read it three times now. .Laura Thomas: Oh wow. Okay. So you're a Stan.Asher Larmie: Re-snacking. Re-snacking on it.Laura Thomas: I love it. Yeah, no, Jessica is great. And I'll link to the episode that we had her on cos it was a really good conversation. All right, so my thing, little less high brow than Jessica's book. I was telling you before we started recording that tomorrow is my kid's third birthday. And so over the weekend we put up his birthday tree. A birthday tree - for people who have not been following my Instagram stories over the past couple of years - is a Christmas tree. Except it's pink and covered in fake snow that I put up for my birthday, my husband's birthday and Avery's birthday. And I just think it's the most fun tradition, we have, like all his little birthday presents underneath it, and it kind of gets you in like the birthday spirit. And I'll put probably some like little lights and stuff on it. So yeah, I have this giant fucking pink Christmas tree in my living room and it's so festive and cheery. Do you wanna see it? Should I show?Asher Larmie: Yeah. No, but is it like a…oh my gosh. It's like a full size. I was thinking like a little mini one.Laura Thomas: No, no, it's like…yeahAsher Larmie: And look at all those presents. Laura Thomas: I know. Asher Larmie: How did you manage to keep those unwrapped, like, you know, they're sitting under the tree not being messed with, I don't think my kids would've been that sensible.Laura Thomas: Well…Yeah. I don't know. Actually, I think that next year we'll probably have a bigger problem. He's like, he's pretty chill. Like he'll..I think.. he does ask can we open them? And, and we're like, no. Well, it's your, it's, it's not quite your birthday yet, but yeah. If it was me, I'd be in, I'd be like pushing… like, what's this? What's this?Asher Larmie: Little tear in the wrapping.Laura Thomas: Peeking in between the wrapping paper. My snack, what I'm snacking on is birthday trees and I think everyone should get involved in this tradition. Asher, can you let everybody know where they can find you and your work online?Asher Larmie: Yes, head to fatdoctor.co.uk and there you will find not only my socials, but all of the classes that I'm running, all of the courses that I'm running. I do one-to-one consulting. If and when the book…the book will come out and when it comes out, you'll be able to see it all on my website. So I think that's probably the central place. I'm also on Instagram, but like I said, if you go to fatdoctor.co.uk, you'll be able to find me on all my socials as well.Laura Thomas: We are gonna link to all of your places on the internet in the show notes anyway, so people will be able to, to find you. Thank you so much for coming and having what I think is a really important conversation.You know, I think the media are presenting one side of the story. Like you said, there's a couple of journalists who are doing some sleuthing and that's really good work, but it's not going far enough. And I think we need to alert parents, teachers, other doctors, medical people to the really concerning dark underbelly of, you know, the Novo Nordisk, Wegovy Industrial complex, whatever you wanna call it.Asher Larmie: Yeah. Well said. Laura Thomas: So thank you. Thank you so much, Asher. Asher Larmie: Thank you.Laura Thomas: Thanks so much for listening to the Can I Have Another Snack? podcast. You can support the show by subscribing in your podcast player and leaving a rating and review. And if you want to support the show further and get full access to the Can I Have Another Snack? universe, you can become a paid subscriber.It's just £5 a month or £50 for the year. As well as getting tons of cool perks you help make this work sustainable and we couldn't do it without the support of paying subscribers. Head to laurathomas.substack.com to learn more and sign up today. Can I Have Another Snack? is hosted by me, Laura Thomas. Our sound engineer is Lucy Dearlove. Fiona Bray formats and schedules all of our posts and makes sure that they're out on time every week. Our funky artwork is by Caitlin Preyser, and the music is by Jason Barkhouse. Thanks so much for listening. ICYMI this week: Fundamentals: Helping Kids build a Good Relationship with Sugar - Part 2* Fundamentals: Helping Kids build a Good Relationship with Sugar* 19: AMA w/ Jeanette Thompson Wesson* Rapid Response: Why I don't like ‘this food does a little/this food does a lot' This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit laurathomas.substack.com/subscribe
In this week's Trending News EU episode, Jack, Ollie, and Will discuss a few recent newsworthy items on UK Life Sciences policy including what the latest spring budget means for Life Sciences (1.00), future pricing of branded medicines in the UK and differences with other countries (6.10), and how Life Sciences policy is working to attract investment and talent to the UK (18.55). Podcast Tags: healthcare, healthcare news, NHS, life sciences policy, healthcare policy, government budget, life sciences, brexit, life sciences regulation, healthcare regulation, medicine pricing, VPAS, healthcare costs, healthcare investment Source Links: Spring Budget 2023 (HTML) - GOV.UK (www.gov.uk) MHRA to receive £10m from HM Treasury to fast-track patient access to cutting-edge medical products - GOV.UK (www.gov.uk)Chancellor gives boost to medical innovation and life sciences industry in Spring Budget | BIA (bioindustry.org)ABPI response to the BudgetIndustry reacts to approvals and R&D tax credit changes in Budget - Med-Tech Innovation (med-technews.com)Voluntary Scheme on branded medicines (abpi.org.uk)Comparing International Prescription Drug Prices | RANDLeading global pharma firms exit UK drug pricing agreement (abpi.org.uk)Life Sciences Innovative Manufacturing Fund (LSIMF) (closed to Expressions of Interest) - GOV.UK (www.gov.uk) Life sciences companies supercharged with £277 million in government and private investment - GOV.UK (www.gov.uk) UK government, private investors dole out $340M+ to drug, diagnostic manufacturers – Endpoints News (endpts.com) For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC. Jen Burke, Director Jen.Burke@vynamic.com Jack Young, Director jack.young@vynamic.com Oliver May, Senior Manager oliver.may@vynamic.com Will Turnbull, Senior Manager Will.turnbull@vynamic.com
This is the Weight and Healthcare newsletter! If you like what you are reading, please consider subscribing and/or sharing!If you have read this newsletter for any period of time, you've read my accounts of how pharmaceutical company Novo Nordisk has been using extremely shady marketing practices (many taken from the playbook that Purdue Pharma used to push oxycontin) to promote their drugs for weight loss. Things likePutting doctors on their payroll to promote their drugs to the media without disclosing their ties to the NovoCreating astroturf organizations that claim to be advocacy groups for higher-weight people but are, in fact, funded by Novo and other pharma and weight loss surgery groups.Marketing their drug through Grand Rounds presentationsCreating PSAs and Sponsored Content using people who (you can't make this stuff up) play doctors on TVCo-opting the concept and language of anti-weight-stigma activists in order to sell their weight loss drugsAnd I'm far from the only person talking about this.Mikey Mercedes has publicly called this out. Louise Adams from Untrapped has been all over it (I had the chance to join Louise Adams and Fiona Willer on Louise's Podcast All Fired Up to talk about this)Asher Larmie, The Fat Doctor, has also been talking about thisAnd there are plenty of others.Part of the issue is that in the United States pharma companies are allowed to market direct-to-consumers , and the rules and regulations that exist are often loosely enforced. That's why I was thrilled to learn that The Association of the British Pharmaceutical Industry (ABPI,) a trade association that works in England, Scotland, Wales, and Northern Ireland in partnership with the government and the NHS on behalf of their members, had suspended Novo Nordisk for being in breach of the ABPI code of practice.Interestingly, just a month ago, the president of ABPI was Novo Nordisk UK General Manager and Corporate Vice-President Pinder Sahota. Sahota stepped down from the board in February “to avoid an ongoing process around a Novo Nordisk ABPI Code of Practice breach becoming a distraction from the vital work of the ABPI.”The complaint was made to The Prescription Medicines Code of Practice Authority (PMCPA) which is “the self-regulatory body which administers the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry, independently of the ABPI. It was established by the ABPI on 1 January 1993.”The complaint centers around a LinkedIn post offering practitioners a free “weight management” course. The only “weight management” treatment covered in the course was GLP1-RA drugs. Novo Nordisk was, at the time, the only company selling these drugs. The course was “sponsored” (paid for) by Novo Nordisk, but that was not clear in the LinkedIn Ad.Not only did this “course” offer information, but they also offered a free Patient Group Direction (PGD). Per the NHS a PGD is “a written instruction for the sale, supply and/or administration of medicines to groups of patients who may or may not be individually identified before presentation for treatment. May or may not be identified means an individual can either be known to the service/have an appointment (e.g. a baby immunisation clinic) or not be known in advance of presenting at a service (e.g. a walk in centre).PGDs are not a form of prescribing. PGDs allow health care professionals specified within the legislation to supply and/or administer a medicine directly to a patient with an identified clinical condition without the need for a prescription or an instruction from a prescriber. The health care professional working within the PGD is responsible for assessing that the patient fits the criteria set out in the PGD.”The complainant pointed out that the PGD was part of what was being offered to individual health professionals by Novo Nordisk, that it had a value, and that it was being given to individuals for their own personal benefit to run private clinics. The complainant suggested that this amounted to bribing health professionals with “an inducement to prescribe.”The complainant noted that on the website the course had been run several times, so it was likely that a large number of health professionals had received this offer.The ABPI review panel found that the training was provided by a third party, but attendees and PGDs were sponsored by Novo Nordisk. The training mentioned three drugs, the first two (orlistat and naltrexone/bupropion) were presented as having significant side effects and contraindications, while the third drug, Novo's Saxenda, did not include side effect information (though they are significant) and the training noted that Saxenda could be provided by an appropriate health professional with a valid PGD (which was provided by the course.)The training included 21 slides about Saxenda, but no such detail on the other two drugs.Sponsorship of third party trainings by drug companies are permissible by APBI “only if there had been a strictly arm's length arrangement with no input by the company and no use by the company.” In this case, the agreement between the training provider and Novo stated that “Novo Nordisk will be in attendance at training meetings and will be given delegates to follow up” and the panel found that “Novo Nordisk had reviewed the training materials used on the course for medical and factual accuracy.”The panel concluded that “the course (webinar and e-learning) was, in effect, promotional material for Saxenda for which Novo Nordisk was responsible”The Panel found that “the webinar, in effect, promoted Saxenda which Novo Nordisk was responsible for, and considered that Novo Nordisk's involvement in relation to such promotion, including that its medicine would be discussed in detail, was not made sufficiently clear at the outset. Therefore, a breach of the Code was ruled. Novo Nordisk's appeal on this point was unsuccessful.”The contract between Novo and the third party was signed in February 2020, with the intention that 13,000 professionals be trained over 2 years, each of whom were to be provided a PGD making Novo Nordisk's maximum contract £357,500 (about $455,578 USD). As of July 1, 2021, 4,399 health professionals had completed the training and 599 PGDs had been activated.The Panel found that “the provision of funding by Novo Nordisk for the PGD was clearly linked to the promotion of Saxenda; the Panel did not consider there could be any intention other than to directly increase the use of Saxenda. Furthermore, the Panel noted that the cost of the provision of the PGD to prescribe Saxenda was given to individual health professionals. Such funding to individual health professionals did not meet the requirements of the Code and was an inducement to prescribe, supply, administer and/or recommend Saxenda and the Panel therefore ruled a breach of the Code. Novo Nordisk's appeal on this point was unsuccessful.”“The Panel considered that the arrangements between Novo Nordisk and the training provider, particularly in relation to the PGD, brought discredit upon, and reduced confidence in, the pharmaceutical industry. A breach of Clause 2 was ruled. Novo Nordisk's appeal on this point was unsuccessful.”Novo Nordisk's decided to appeal on the basis that they didn't know it was a breach. This backfired spectacularly.The Appeal Board was “very concerned that Novo Nordisk did not recognise that this was a large-scale Saxenda promotional campaign which Novo Nordisk knowingly paid for and which was disguised. In the Appeal Board's view the gravity of the breaches was compounded by Novo Nordisk's failures to recognise that its own behaviour was not compliant with the Code…The Appeal Board was concerned about the potential impact on patient safety of providing unbalanced information to a wide audience, particularly given that the arena of weight loss was a highly emotional arena, and particularly given the lack of balance of Saxenda's safety profile and side effects when comparing it with its competitors.”The Appeal Board decided to publicly reprimand Novo Nordisk for “its failings and the potential impact on patient safety.” They also ordered an audit and decided that “the circumstances were so egregious that a report to the ABPI Board was the only appropriate course of action.”The ABPI Board unanimously decided that further action must be taken, and while they chose not to expel Novo outright, they noted that this option could be exercised at a later date. While a majority wanted to immediately suspend Novo Nordisk's membership, they didn't reach a 75% threshold and so decided to conduct an audit.Subsequent to that audit they determined that Novo Nordisk's actions were ““likely to bring discredit on, or reduce confidence in, the pharmaceutical industry” and suspended them for two years, with reinstatement pending a future audit.In Part 2 we'll talk about some investigative journalism that caught Novo Nordisk in more shady marketing practices. Did you find this post helpful? You can subscribe for free to get future posts delivered direct to your inbox, or choose a paid subscription to support the newsletter and get special benefits! Click the Subscribe button below for details:Liked this piece? Share this piece:More research and resources:https://haeshealthsheets.com/resources/*Note on language: I use “fat” as a neutral descriptor as used by the fat activist community, I use “ob*se” and “overw*ight” to acknowledge that these are terms that were created to medicalize and pathologize fat bodies, with roots in racism and specifically anti-Blackness. Please read Sabrina Strings Fearing the Black Body – the Racial Origins of Fat Phobia and Da'Shaun Harrison Belly of the Beast: The Politics of Anti-Fatness as Anti-Blackness for more on this. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe
Join Dr Ellie Cannon as she talks to Susan Rienow (Country President, Pfizer UK) and Dr Richard Torbett (CEO, The Association of the British Pharmaceutical Industry) about the lessons learnt from the COVID-19 pandemic and how this could be applied to address other major healthcare challenges.PP-UNP-GBR-2871 / December 2022
In this week's episode, Helena and Isabel share an interview with GOLD's new catalyst John Wahba, Medical Head of the Global Digital Hub, GSK. In this teaser edition of the catalyst interview, John shares his motivations for joining the pharmaceutical industry, key takeaways from his time in the medical field, thoughts on digitally optimising MSL teams and much more. If you want to read the written interview in full, check out the link below. If you're interested in learning more about the topic areas discussed in this episode, check out the following content: John Wahba on the medical affairs evolution Pharma in Japan Urgent need to boost trade for UK's life sciences, says ABPI
This week, GOLD chats to Silvia Taylor, Executive Vice President and Chief Communications Officer, Novavax. She reveals what it was like to join Novavax at the height of the pandemic, the importance of storytelling to ensure uptake and access to new vaccines and the advice she would give her younger self on how to succeed. If you're interested in learning more about the topic areas discussed in this episode, check out the following content: Pharma's sustainability agenda centre stage in new ABPI report https://www.emg-gold.com/post/pharma-s-sustainability-agenda-centre-stage-in-new-abpi-report 2022 Access to Medicine Index reveals improvement https://www.emg-gold.com/post/2022-access-to-medicine-index-reveals-improvement Keeping the spark alive in vaccine development https://www.emg-gold.com/post/keeping-the-spark-alive-in-vaccine-development How to enhance value and access across pharma https://www.emg-gold.com/post/podcast-how-to-enhance-value-and-access-across-pharma
Compliance with rules and regulations in patient engagement while necessary can also be an impediment to meaningful collaboration. We'll hear from companies that have taken steps to work through compliance challenges internally and the efforts by associations such as ABPI to enable more collaboration. More specifically: Where do the problems still exist in contracting with patient organizations?What are solutions we can match to some of the problems?What are some case studies of successful collaboration between patients and pharma that we can learn from?What tools are available that can assist? Moderated by: Natalie Bohm, MD, PhD, UK Medical Director, External Engagement, Pfizer Panelists: James Read, Director, POlicy and Communications, MSDAlex Potlog, Legal Director, UK & Ireland, AbbVieJayne Spink, PhD, Translational Research Director, Prostate Cancer ResearchVictoria Bates, Patient Engagement Lead, ABPI Learn more about the Patients as Partners in Clinical Research conference at www.patientsaspartners.org
In episode 119, Doina Ionescu, Managing Director, UK & ROI, at Merck, discusses her career journey, gender discrimination in the workplace, her role in the ABPI, and lessons she's taken from Queen Elizabeth II.
In this week's episode, Helena is joined by Paul Simms, CEO of Impatient Health, to delve deeper into GOLD's recent cover feature on reframing pharma's bad boy reputation. They chat about the current state of pharma's reputation and the influence of the media and pop culture on this, the ways in which pharma can recover and bolster its reputation, and more. And in ‘news you might have missed', Helena discusses the latest global awareness campaign from Leo Pharma, the ABPI's recent survey on pharma and academia collaboration and a new Marvel comic strip features Pfizer's COVID-19 vaccination efforts in the US. If you're interested in learning more about the topic areas discussed in this episode, check out the following content: Reframing pharma's bad boy reputation https://www.emg-gold.com/post/reframing-pharma-s-bad-boy-reputation Talking to Paul Simms https://www.emg-gold.com/post/podcast-talking-to-paul-simms
A tecnologia 5G é mais do que uma nova geração de tecnologia móvel. Ela vai representar uma revolução na sociedade em que vivemos impulsionando a produtividade na indústria, economia e em diversos campos do conhecimento. Este foi o tema de um dos painéis do 42º Congresso Internacional da ABPI. Para discutir o assunto, convidamos Ícaro Leonardo da Silva, diretor de patentes da Ericsson, que atuou no desenvolvimento e negociações de licenciamento do portfólio de patentes essenciais do padrão 5G, representou a Ericsson no processo de padronização junto ao 3GPP e é reconhecido como um dos inventores da tecnologia. Ícaro fez parte da graduação na École Centrale de Lyon, na França, mas é cientista brasileiro, saído da Universidade Federal do Ceará e reconhecido no mundo todo. Neste talk, ele fala sobre o que é a Sociedade 5.0 e seu impacto na vida das pessoas visando melhorar o bem estar humano. Fala também sobre como atua o fórum 3GPP para a padronização e interoperabilidade da tecnologia, o incentivo à inovação no Brasil, patentes essenciais e a importância da Propriedade Intelectual no 5G. "Precisamos discutir de forma transparente com as outras empresas para que aconteça a interoperabilidade e para isso precisamos de proteção. Daí a importância da PI para as telecomunicações".
Roberto Miranda - Queremos fomentar o empreendedorismo de alto impacto O ABPICast de hoje faz parte de uma série de eventos promovidos pela ABPI em parceria com a OMPI em homenagem ao Dia Internacional da PI cujo tema é PI e Juventude: Inovar para um futuro Melhor. O convidado de hoje é Roberto de Ávila Miranda, reitor da URM - Faculdade Roberto Miranda, que forma empresários há mais de 20 anos e tem sede no Vale do Silício na Califórnia, berço mundial da inovação e do empreendedorismo. Durante o talk ele falou sobre os principais desafios para empreender no Brasil, como as condições de empreendedorismo mudaram nestes últimos 20 anos e principalmente sobre a importância da proteção da propriedade intelectual das empresas, não apenas no seu dia a dia, mas também no valuation dessas empresas em um momento de fusão e aquisição. "Queremos fomentar o empreendedorismo de alto impacto", diz Miranda.
O novo episódio do ABPICast é uma continuidade da série de podcasts produzidos pela ABPI em parceria com a OMPI em homenagem ao Dia Mundial da PI, que este ano discute o tema "PI e Juventude: Inovar para um futuro Melhor". O convidado de hoje é Greiton Toledo de Azevedo, o Educador de PI do ano de 2021 e vencedor do Concurso PI nas Escolas, projeto do INPI visa premiar iniciativas que estimulam o uso e a proteção do uso da PI nas escolas de ensino infantil, fundamental, médio e técnico, envolvendo também ações de empreendedorismo e inovação. Greiton Toledo de Azevedo é professor de matemática do ensino médio do Instituto Federal Goiano e autor do projeto Invenções Robóticas de PI nas Aulas de Matemática para o Tratamento de Parkinson. "Usamos a matemática em prol das pessoas. Nosso modelo visa utilizar jogos digitais e dispositivos robóticos em prol do tratamento de sintomas de Parkinson em hospitais públicos". Para ele, participar do concurso foi uma grande oportunidade de colocar a escola pública na altura do seu tempo e mostrar que professores e estudantes são capazes de inovações científicas para beneficiar pessoas em sociedade. "Bons professores incentivam, encorajam e nutrem a PI quando desenvolvemos trabalhos não somente de inovação científica e intelectual, mas que prezam pelo direito do autor. Penso a escola como um lugar onde se desenvolve a criatividade científica e tecnológica em vez de apenas reproduzir coisas".
O ABPICast de hoje faz parte de uma série de eventos promovidos pela ABPI em parceria com a OMPI em homenagem ao Dia Internacional da PI cujo tema é PI e Juventude: Inovar para um futuro Melhor. A convidada de hoje é Mariana Guisso, professora de filosofia de ensino médio e vencedora da categoria Cidadania da Região Sul do projeto "PI nas Escolas". O projeto do INPI visa premiar iniciativas educacionais que fomentem a temática da PI em 5 categorias: Criatividade, Cidadania, Tecnologia, Planeta e Negócios nas escolas de ensino infantil, fundamental, médio e técnico, envolvendo também ações de cidadania e inovação. Mariana foi vencedora com o projeto "A Importância do respeito à Propriedade Intelectual em casos sobre o desenho industrial, invenções e patentes". Para ela, participar do concurso foi uma grata surpresa. "Foi um grande marco para a minha carreira e também para os estudantes e toda a comunidade escolar envolvida. "Como professora da área de filosofia, sempre tive vontade de me aprofundar em algumas áreas do direito e a PI surgiu com a possibilidade de conexão com temas importantes como direitos autorais e a necessidade do respeito à construção do conhecimento, da responsabilidade social com as questões de criatividade e inovação e de ética e plágio, muito fomentado principalmente na educação durante a pandemia".
A indústria de jogos digitais tem sido apontada como um dos setores que mais cresce no mundo e seu uso tem sido expandido para diversos setores como educação e empresarial. Para conversar sobre os objetos de proteção que compõem os jogos digitais e as formas de negociação desses direitos, o ABPICast de hoje recebe Isabella Pimentel, conselheira da OMPI no Brasil, e José Eduardo de Vasconcellos Pieri, diretor relator das comissões de estudo da ABPI. Eles contaram como o mundo dos games entrou em suas carreiras, falaram sobre os principais direitos de propriedade intelectual envolvidos em jogos digitais, os desafios para a indústria nacional, a duração dos direitos envolvidos e discutiram a falta de preocupação dos desenvolvedores nacionais com a proteção.
Desde 2006, o EUA envia ao Brasil o seu IP Attaché, um adido anti-pirataria. Recentemente o escritório de marcas e patentes do EUA, o USPTO escolheu o David Kellis como o IP Attaché que representará o governo norte americano para assuntos de propriedade intelectual no Brasil e demais países do Mercosul, além de Guiana, Guiana Francesa e Suriname. Em nossa conversa, Kellis explicou as várias responsabilidades de um IP Attaché como promover altos padrões de proteção e observância da PI na região; acelerar empresas americanas com questões regionais de PI; aconselhar funcionários do governo dos EUA em questões de PI; auxiliar na troca de informações entre funcionários de governos estrangeiros; além de conduzir programas ações de conscientização pública com estudantes e representantes comerciais sobre PI. "Sabemos que a Propriedade Intelectual é uma força motriz que incentiva a inovação e permite que ela seja monetizada ajudando na criação de empregos, aumento de investimento estrangeiro e no crescimento econômico dos países. O governo do Brasil entende a importância da PI para estimular o crescimento, como evidenciado com a Estratégia Nacional de PI lançada em dezembro de 2020", avaliou Kellis, além de lembrar que está animado para trabalhar com os colegas de PI brasileiros e de morar na cidade maravilhosa do Rio de Janeiro. Participou deste podcast Ricardo Boclin, diretor de serviços técnicos e jurídicos da ClarkeModet Brasil e diretor conselheiro da ABPI.
A proteção é o passaporte, mas o objetivo de todo titular de direitos de propriedade intelectual é obter lucro com o seu ativo e, saber qual o seu real valor. Por isso, a avaliação de intangíveis é um tema que causa dúvida e interesse de titulares e profissionais. Para falar sobre as formas de avaliação de intangíveis, a ABPI convidou para este episódio Luiz Paulo Silveira, graduado em Ciências Contábeis e Engenharia Mecânica pela Universidade Federal Fluminense, com mestrado em Administração de Empresas pela COPPEAD-UFRJ, vice-presidente da Apsis Consultoria Empresarial, empresa especializada em avaliações de intangíveis. Silveira defende a gestão dos intangíveis dentro de uma organização para que se tenha um controle maior destes ativos, e indica dois momentos oportunos para avaliação: “Primeiro, num processo de compra e venda que pode ser feito separadamente ou através de uma combinação de negócios. Neste momento, há autorização para registrar o valor dos ativos no balanço da companhia. Outra possibilidade é registar o ativo à medida que ele for construído dentro da empresa, seguindo critérios específicos”. Também participou deste episódio Pedro Vilhena, advogado, mestre em Direito pela Universidade de Estrasburgo, sócio do escritório Mansur Murad e coordenador do Curso de Privacidade de Dados do CEDUC – ABPI, que tratou da importância da proteção e vigilância na valoração de ativos intangíveis.
In this episode, which has been initiated and funded by Britannia Pharmaceuticals, we're looking at what it means to reach an advanced stage of the condition. Because Parkinson's disease is so individualised, its progression is not black and white. The term ‘advanced' Parkinson's generally refers to the stage at which symptoms have a bigger impact on day-to-day life. At this stage, medications may not be as effective and people with the condition may begin to rely more on care. Our first guest is Colin Cheesman, a former local authority chief executive based in Chester, UK, who at 74 has lived with Parkinson's disease for two decades. Colin has been able to maintain a good quality of life but in the past few years, his Parkinson's symptoms – such as involuntary movement and loss of balance – have become more challenging. He is joined by Dr Nishantha Silva, a geriatrician based in Grantham, UK, who has specialised in Parkinson's disease for 10 years. As a doctor, Nishantha is motivated by the experiences of his own father, who lived with the condition – and strongly believes that the right care can ensure long, fulfilling lives for people with Parkinson's. Parkinson's Life magazine is produced by Speak Media on behalf of the European Parkinson's Disease Association, the leading voice for Parkinson's in Europe. For the latest research and information on Parkinson's, visit EPDA.eu.com. If you like what you've heard, please do take the time to rate and review – it helps make sure others can find us! And if you'd like to get in touch, email us at editor@parkinsonslife.eu or catch up with us on Facebook (https://www.facebook.com/parkinsonslife) and Twitter (https://twitter.com/parkinsons_life) Message from our sponsor: The content of this podcast was up to date and accurate at the time of recording in June 2021. The views expressed in this episode represent the speakers' own opinions and experiences. Speakers may express personal opinions that are not necessarily shared by Britannia Pharmaceuticals. Content from this episode has been reviewed by Britannia to ensure compliance with the ABPI and EFPIA Codes of Practice for the Pharmaceutical Industry. Any adverse events discussed within this podcast have been reported to the regulatory authorities. All adverse events should be reported to the relevant regulatory authority.
As medidas para o controle da pandemia no Brasil estão impondo respostas imediatas por parte da iniciativa privada e também dos órgãos públicos. Assim, o podcast de hoje conta com o Dr. Julio Cesar Castello Branco, diretor de administração do INPI, para nos esclarecer sobre os impactos da medida de controle e do feriado de 10 dias imposto por prefeitos e governadores. Com a medida, o INPI prorrogou para 05 de abril próximo os prazos que vencem no período de 26 de março a 04 de abril. "Estamos dando nossa cota de sacrifício para que este período de dez dias tenha o melhor resultado possível de forma a mitigar o efeito da pandemia até a vacina chegar", afirma Castello Branco. O podcast também conta com a participação do Dr. Ricardo Vieira de Melo, membro de honra vitalício da ABPI.
O ABPI Cast de hoje procura trazer um pouco sobre como a Propriedade Intelectual é vivenciada dentro de uma empresa da área da saúde. Para esta conversa, convidamos Luciany Creado, supervisora jurídica e especialista de PI da Neodent, empresa líder em implantes dentários no Brasil. Neste talk ela falou sobre sua atuação dentro da Neodent nos últimos anos, sobre como a empresa trabalha com pesquisa, inovação e Propriedade Intelectual, como é a expectativa por inovação e excelência e, principalmente, como a PI ajudou a empresa a se tornar líder de mercado. Luciany também falou sobre as parcerias com as universidades e da importância do diálogo entre as instituições. A conversa foi mediada pela representante da seccional Paraná da ABPI, Maria Inez de Abreu.
O ABPI Cast de hoje aborda a fase 2 do PPH (Patent Protection Highway), que entrou em vigor no dia 01 de janeiro. Para falar sobre o assunto e apresentar as principais mudanças introduzidas nesta nova fase e trazer informações sobre os outros trâmites de exames prioritários de patentes disponíveis, convidamos Diego Musskopf, chefe substituto do serviço de assuntos especiais SAESP do INPI e gerente da força tarefa do trâmite prioritário do INPI. Segundo ele, dentre as várias modalidades de trâmite prioritário, o PPH é a mais rápida em todos os critérios. Por envolver uma alta carga de cooperação internacional, o PPH permite que o requerente perca menos tempo - há pedidos sendo concedidos entre 15 e 90 dias, dando uma média de 45 dias para o processo -; há uma taxa maior de deferimento; e a taxa de concessão na primeira ação é muito maior, quase 90% no PPH. "Tudo isso colabora para a diminuição do backlog de patentes". Colaborou com esta entrevista Ricardo Boclin, diretor de interesses técnicos e jurídicos da ClarkeModet e diretor conselheiro da ABPI.
Com o objetivo de aumentar o número de registros de ativos de PI no Brasil, o INPI criou em 2020 o INPI Negócios. Para apresentar os resultados alcançados até agora e os desafios para 2021, o ABPI Cast de hoje traz Felipe Augusto Melo de Oliveira, coordenador geral de disseminação para a Inovação do INPI. Ele destacou os principais resultados do programa neste ano e relembrou os objetivos do INPI Negócios e suas bases de sustentação. Entre os novos projetos, Oliveira destacou o IP Black Belt Office, que ainda está em fase de desenvolvimento e será estratégico para 2021. O projeto envolve a criação de um programa de desenvolvimento e certificação de agentes de propriedade industrial no Brasil. "O IP Black Belt Office surgiu a partir de um webinar da ABPI que abordava a qualidade do sistema de intermediação no Brasil. Pretendemos ter uma formação lato sensu para estes agentes e estamos discutindo isso com a ABPI e outras associações". Ele também lembrou que o INPI prepara para este ano um código de ética de auto regulação para o exercício de atividade profissional de proteção de direitos de PI no Brasil. Quanto aos estudos do Radar Tecnologico, ele adiantou que em 2021 devem ser abordados os temas saneamento, uso de novos materiais - principalmente grafeno e nióbio -, questões aeroespaciais e biotecnologia. Colaborou com este cast Renata Lisboa, sócia do escritório Lisboa IP, membro do conselho da ABPI e coordenadora do ABPI Ceduc. "O tema de hoje para mim é muito caro, porque a ABPI vem empenhando esforços para consolidar e entregar um treinamento cada vez melhor e mais adequado às necessidades e aos tempos que vivemos e falar do INPI negócio também é falar de educação". Errata: “A partir de nosso estudo setorial na área de saúde (mapeamento de clusters) foram 15 projetos com investimentos de R$ 7,2 milhões e não 15 como dito .” ABDI - Agência Brasileira de Desenvolvimento Industrial EMBRAPII - Associação Brasileira de Pesquisa e Inovação Industrial
Com a entrada em vigor da lgpd, a corrida para a implementação e manutenção das adequações se tornou absolutamente necessária. Para falar sobre os desafios para adequações à LGPD o ABPI Cast de hoje convidou o Dr. Rodrigo Cantarino, advogado especialista global em Data Privacy da AB Inbev. Para ele, o profissional da Propriedade Intelectual já sai em vantagem neste cenário. "Antes da lei não tínhamos especialização em LGPD e novos profissionais estão se formando, mas o profissional de PI já está acostumado a lidar com tecnologia, direitos personalíssimos e fazer o balanceamento do interesse público e privado, por isso a relevância deste tema para os associados da ABPI". Colaborou com este podcast Filipe Fonteles, membro do conselho diretor da abpi e autor do livro "proteção de dados pessoais na atividade empresarial". Eles também discutiram sobre a importância da adequação de empresas que atuam em diferentes países, as similaridades do regulamento europeu com a lei brasileira, como o consumidor está cada vez mais atento ao uso de seus dados e como proteger os segredos de negócios e ao mesmo tempo garantir a transparência, entre outros assuntos.
O ABPICast de hoje coloca em discussão o tema empreendedorismo feminino. Para tratar o assunto, convidamos Renata Malheiros, coordenadora nacional do Sebrae Delas, programa do Sebrae que teve início no ano passado para apoiar mulheres de todas as regiões do Brasil que queiram empreender, trabalhando com elas competências técnicas, como gestão, marketing, produção de plano de negócios, e também competências emocionais, como liderança, capacidade de se comunicar, autonomia nas decisões, criação de rede de relacionamento etc. "O Brasil é um país com uma grande quantidade de empreendedores, mas a maior parte empreende por necessidade e não por oportunidade, que é o ideal", explica. Renata lembra que empreender é difícil tanto para homens quanto para mulheres, mas fatores culturais, que impõem crenças limitantes desde a infância para as meninas, e a má distribuição de tarefas domésticas fazem com que as mulheres dediquem 17% menos tempo a seus negócios que os homens empreendedores. "Por isso o nosso projeto é tão importante, ainda mais com a pandemia que acabou empurrando muito mais pessoas para a montagem de seus próprios negócios", afirma. Ela também falou sobre o apoio do Sebrae para o aumento das startups lideradas por mulheres, que hoje é inferior a 10%, e a parceria realizada com instituições financeiras para crédito e com a Microsoft para a infraestrutura tecnológica. O Sebrae também acredita que é importante entender e proteger seu negócio, por isso oferece soluções que ajudam os empreendedores a defenderem seus negócios, orientando com registro de marcas e patentes. Colaborou com este podcast, Aline Ferreira, advogada e coordenadora da Comissão de Estudos de Direito Internacional da ABPI.
No podcast de hoje nós vamos falar sobre patentes essenciais – aquelas relacionadas a tecnologias vitais para a implementação de um determinado padrão tecnológico - e a corrida pela oferta de licença FRAND (Fair, Reasonable and Non Discriminatory), que busca garantir condições justas, razoáveis e não discriminatórias no licenciamento de tecnologias protegidas pelas patentes essenciais. Para discutir o assunto, o ABPICast conta o DR. EDVALDO SANTOS, Diretor do Centro de Pesquisa, Desenvolvimento e Inovação da Ericsson para América Latina, Coordenador Comitê de Inovação da Swedcham e mestre em Administração Estratégica, pela Fundação Escola de Comércio Álvares Penteado. “Este é um tema de extrema importância para todas as nações e principalmente para o Brasil que é um celeiro de talentos. “Se popularizarmos este assunto, podemos ter na Propriedade Intelectual uma alavancagem de desenvolvimento científico e tecnológico e também econômico”, disse o executivo, que também falou sobre a necessidade de acordos bilaterais, principalmente para as redes 5G e a importância da conectividade para todas as indústria e para a vida das pessoas, principalmente durante a pandemia. Colaborou com este podcast o Dr. Luiz Edgard Montaury Pimenta, presidente da ABPI.
Já pensou em ter a sua própria marca? Saiba porque registrar uma marca pode significar o sucesso do seu negócio. Ter um CNPJ protege a sua marca? Neste episódio do Podcast Don Alcides Freak Show abordamos tudo sobre a importância e processos do registro de marca. Como fazer o registro de uma marca? Quanto tempo demora? Quanto custa? Essa e outras dúvidas frequentes foram abordadas neste conteúdo com a Totall Marcas, uma das líderes de mercado no Brasil. Convidamos para o bate papo, o fundador da Totall Marcas e Patentes, Vinícius Oliveira, bacharel em Direito pela PUC, membro da ABPI, Associação Brasileira da Propriedade Intelectual, agente da Propriedade Industrial pelo INPI e professor de pós graduação de propriedade intelectual, e o advogado Sérgio Vitor, bacharel em Direito pela Newton Paiva, membro da ABPI e consultor de marcas e patentes na Totall. Conheça a Don Alcides, pioneira no Brasil no segmento de produtos para a saúde e manutenção da barba, responsável por licenciar cosméticos em parceria com marcas mundialmente conhecidas como Rolling Stones, Mamonas Assassinas, Narcos e Peaky Blinders, séries distribuídas pela Netflix: https://donalcides.com.br Conheça a Totall Marcas: http://totallmarcas.com.br
Para falar sobre como a chamada tríplice hélice formada por governo, empresas e universidades pode colaborar para transformar o conhecimento científico em inovação tecnológica, a ABPI convidou para este episódio do ABPICast, Miguel Emery Carvalho, representante do Grupo Interministerial de Propriedade Intelectual (GIPI), do Ministério da Economia, e Beatriz Amorim-Borher, diretora do escritório da OMPI para América Latina e Caribe. Na conversa, Carvalho falou sobre a nova estrutura do GIPI, que foi reativado em novembro de 2019 e que busca coordenar as políticas de Propriedade Intelectual do Brasil. "Nosso projeto prioritário é criar uma Estratégia Nacional de Propriedade Intelectual que é essencial para qualquer país que busque um desenvolvimento de seu sistema de inovação. Porque a Propriedade Intelectual é o pilar invisível da inovação". Ele ressaltou que para este projeto há uma parceria intensa com instituições como INPI, ABDI e Embrapa em um trabalho conjunto e cooperativo. Já Beatriz Amorim-Borher falou sobre como a metodologia WIPO Methodology and Tools for the Development of National IP Strategies está sendo utilizada para ajudar o Brasil na criação dessa estratégia. Ela destacou que a OMPI oferece consultoria e troca de experiências em mais de 90 países. "Não há hoje nenhum exemplo de país em desenvolvimento que não tenha estruturado de forma estratégica seu sistema de Propriedade Intelectual e é preciso cada vez mais contextualizar Propriedade Intelectual no sentido de inovação e criatividade".
O assunto proteção de dados é tema recorrente em vários segmentos de mercado, mas a vigência da Lei Geral de Proteção de Dados foi adiada novamente. Para falar sobre os impactos desse adiamento, principalmente no mercado de Franquias, o ABPICast traz Bruno Bioni, doutorando em direito comercial e mestre com louvor em direito civil na Faculdade de Direito da USP e consultor jurídico na área de regulação e tecnologia, com ênfase em privacidade e proteção de dados. Colaborou neste programa, José Eduardo Pieri advogado especializado em PI e em Proteção de Dados, sócio da BMA e diretor relator da ABPI. Em sua entrevista Bioni explica que a proteção de dados é altamente relevante e é difícil imaginar qualquer modelo de negócio que não seja orientado e impactado por dados. "Desde as empresas mais inovadoras que atuam com publicidade comportamental até as mais tradicionais, como por exemplo o setor de franquias que tem um modelo bem complexo com cruzamento de informações para uma melhor oferta de serviços", explica. Bioni ressalta que desde o início é contra as alterações da data de vigência da LGPD. "Essa postergação traz mais malefícios do que benefícios, apesar do cenário de retração econômica. Sem a LGPD não temos a segurança jurídica para que os modelos de negócios floresçam. Os consumidores têm menos garantido uma série de direitos e é ruim até mesmo para como o Brasil será visto em termos de uma economia internacional".
O ABPI Cast de hoje traz a segunda parte da entrevista com o Dr. Fernando Valente Pimentel, presidente da Associação Brasileira da Indústria Têxtil e de Confecção. A entrevista teve a colaboração do Dr. Luiz Edgard Montaury Pimenta, presidente da ABPI. Neste episódio, o assunto girou em torno sobre a questão da exportação da indústria da moda, o impacto da pandemia no mercado internacional, a recessão no mercado da moda, as alternativas que as marcas estão adotando e o comércio online. Também foi abordada a questão do consumo no Brasil e no mundo e as mudanças no registro de marcas de moda com o Protocolo de Madrid.
Joe Boehler, plasticien et performeur est né à Strasbourg. Entre 1967 et 1969, il entre dans le compagnonnage et fait son tour de France. Vers les années 1970, il crée son atelier en Suisse et commence sa recherche artistique, qui le confronte à un travail beaucoup plus personnel. En 1972, il fait sa première exposition. Il participe ensuite à plusieurs Grands Prix de peinture: Lauréat de la ville de Poitiers(1975), Prix du Jury du Grand Prix de Peinture de Cannes (1975), Lauréat du Prix des "7 collines de Rome" (1977). Il expose à Poitiers et à la "Maison D'ailleurs" d'Yverdon-les-Bains, sa série "Attente cosmique". En 2001, il fonde ABPi SA en collaboration avec Fanny Audemars, puis en 2002 crée la performance "Comme au cinéma" en tant que peintre, concepteur et réalisateur. Joe Boehler est lʹinvité de Lydia Gabor.
Os direitos de propriedade intelectual envolvem diversos atores sendo os dois preponderantes, a indústria e o consumidor. Neste contexto, a interlocução com a indústria é agenda constante da ABPI. No ABPI Cast de hoje, mergulharemos na indústria têxtil e de confecção, segunda maior empregadora da indústria de transformação. Para apresentar os desafios da indústria têxtil e de confecção, o podcast recebe o Dr. Fernando Valente Pimentel, presidente da Associação Brasileira da Indústria Têxtil e de Confecção. Para colaborar neste programa, contamos com o Dr. Luiz Edgard Montaury Pimenta, presidente da ABPI.
O uso de cannabis em medicamentos é um assunto sempre polêmico e rende boas discussões. Para tratar sobre o tema, o ABPICast de hoje traz Carolina Nocetti, médica e consultora técnica em terapia canabinoide. Neste episódio ela fala sobre como a resolução 327 da Anvisa, publicada em dezembro de 2019 e que regulamentou a produção e importação de produtos à base de cannabis para fins medicinais no Brasil, permitiu um novo ramo de negócio, o ingresso de players internacionais no Brasil e maior segurança para os investidores. Ela fala sobre a competitividade brasileira no setor e a questão das patentes. A conversa também girou em torno das indicações terapêuticas da Cannabis e como a terapia está sendo utilizada para amenizar diferentes questões relacionadas à pandemia do Covid-19. Participa deste episódio Aline Ferreira, advogada especializada em Propriedade Intelectual e coordenadora da comissão de estudos de direito internacional da ABPI.
Haseeb Ahmad, Managing Director, UK, Ireland & Nordics Novartis Pharmaceuticals and Country President Novartis UK and President of the ABPI is interviewed by Paul Bennett (CEO, RPS), Prof Gino Martini (Chief Scientist, RPS) and Sarah Cahill (Chief Pharmaceutical Officer's Clinical Fellow) about the Novartis response to COVID-19. Today we cover experimental vaccines and a few existing medicines that are approved for other indications. The RPS, Novartis and the ABPI want to be very clear that they are not endorsing use of these medicines and no treatments have been approved for COVID-19. Their intent is to explain to the society’s listeners the current status of the various clinical studies which are ongoing.
A relevância da privacidade de dados já foi tema do ABPI Cast, mas neste episódio, o objetivo é fazer uma ponderação da privacidade, que é um direito individual, com a possibilidade de uso de dados coletados por frentes diversas para controle da Covid 19, um direito e uma necessidade coletiva. Um tema de extrema relevância que está sendo debatido por vários países. Nosso convidado deste episódio é o advogado Danilo Doneda, professor do IDP - Instituto Brasiliense de Direito Público e membro do Conselho Nacional de Proteção de Dados e Privacidade na Câmara dos Deputados e membro da comissão de juristas formada pela Câmara dos Deputados para redigir o projeto de lei sobre Proteção de Dados nos setores de segurança pública e investigação criminal. Participou da entrevista, Tatiana Campello, advogada especializada em Propriedade Intelectual e Privacidade, membro do comitê diretor do projeto sobre LGPD e Membro do Comitê Executivo da ABPI. Nessa conversa, foi possível traçar um paralelo entre a Proteção de dados frente à pandemia: - Quais são os limites do uso das informações? - Como a questão do tratamento de dados ganhou cada vez mais relevância com a digitalização da sociedade - Como o Governo Federal e o Ministério da Saúde pretendem usar os dados dos cidadãos no combate à Covid e principalmente, quais as diferenças entre dados pessoais e dados sensíveis.
No novo episódio do ABPI Cast, Ana Paula Halla, advogada e coach, fala sobre a transformação jurídica que está acontecendo com o teletrabalho e com a adoção de soft skills, com advogados cada vez mais preocupados com a relação com o seu cliente, com a escuta mais ativa e com a empatia. "Quando citamos o advogado 4.0, logo se pensa em um advogado altamente tecnológico, mas aqui falamos de quem consegue enxergar a atuação jurídica de forma diferente. As habilidades comportamentais como criatividade, pensamento crítico, humanização no relacionamento com a equipe e flexibilidade", destaca a Ana Paula que se define como "advogada apaixonada pela gestão de pessoas". A advogada é mentora e especialista em contratos e Executive LLM pela CEU Law School, com MBA em gestão empresarial pela FGV e certificada em liderança transformadora pela Fundação Dom Cabral. A entrevista contou com a participação de Paulo Parente, advogado especializado em Propriedade Intelectual e membro do Conselho Diretor da ABPI.
O ABPI Cast apresenta os bastidores da criação da ANPD - Autoridade Nacional de Proteção de Dados – ANPD, que deve entrar em vigor juntamente com a LGPD - Lei Geral de Proteção de Dados. Para falar sobre como será estruturada e qual a atuação da ANPD, convidamos José Antonio Ziebarth, diretor do Ministério da Economia, advogado e professor. A conversa foi mediada por Dirceu Santa Rosa, advogado especializado em PI e co-coordenador da Comissão de Estudos de Software, Informática e Internet da ABPI. Entre os vários assuntos abordados, estão a importância da ANPD, como serão implementadas as políticas da agência, quais são os pontos críticos, impactos diretos dessa regulamentação no setor produtivo brasileiro etc. Ele também aproveitou para responder perguntas enviadas pelos associados da ABPI
No novo episódio do ABPI Cast, o tema em discussão é o Direito Autoral. Para falar sobre o assunto, a ABPI convidou Gustavo Martins de Almeida, advogado atuante nas área civil de direito autoral, professor, mestre e doutor em direito pela UGF, advogado do Sindicato Nacional dos e Editores de Livros e advogado e conselheiro do Museu de Arte Moderna do Rio de Janeiro. Também participa deste episódio, Jorge Ávila, ex-presidente do INPI, pró-reitor de extensão e cultura da Unirio e coordenador do Comitê Empresarial da ABPI, além de sócio da Copabacana Produções Artísticas. Neste episódio, os convidados discutem o direito do autor frente as mais diferentes manifestações artísticas, e como ciência, tecnologia e arte se entrelaçam. É uma viagem no tempo para falar como o trabalho criativo vem sendo protegido ao longo dos séculos e quais os desdobramentos deste tema na atualidade com a revolução tecnológica e seus impactos na economia criativa.
O novo episódio do ABPI Cast é com Lisandra Thomé, advogada, empresária, professora e especialista em Marketing Jurídico. Por conta do conhecimento nessa área, Lisandra explica como o advogado pode usar o Marketing Jurídico, com foco informativo, para ampliar sua visibilidade e fortalecer a marca pessoal ou jurídica, dentro dos princípios do código de ética da OAB. Para ela, o marketing jurídico não é propaganda, não é só redes sociais, é antes de tudo relacionamento. Participa da entrevista Antonella Carminatti, advogada especializada em Propriedade Intelectual e membro do Conselho Diretor da ABPI.
O novo episódio do ABPI Cast é com Daniel Marques, presidente da Associação Brasileira de Lawtechs e Legaltechs (AB2L). Durante a entrevista ele revela como o uso da tecnologia garante mais eficiência e eficácia ao profissional de direito, liberando o advogado das tarefas burocráticas e repetitivas. Destaque também para a possibilidade de obtenção e análise de dados que resultam num business intelligence do escritório de advocacia. Participa ainda do episódio, Gabriel Leonardos, primeiro vice-presidente da ABPI. Ouça a entrevista completa.
O episódio da vez apresenta Luciano Benetti Timm, que comanda a Secretaria Nacional do Consumidor e o Conselho Nacional de Combate à Pirataria e Delitos contra a Propriedade Intelectual. O especialista afirma que, segundo a OCDE, o Brasil está hoje entre os 16 primeiros países mais prejudicados com pirataria. Por isso, ele afirma que o governo atual entende a necessidade de combate à pirataria e que para mudar esse cenário é fundamental uma parceria entre setor público e privado. Participa também da entrevista, Valdir Rocha, diretor secretário da ABPI.
Seguimos com Maria Eugênia Gallotti, gerente do projeto Protocolo de Madri, do INPI. Nessa edição ela trata de isenções, taxas, exigências de documentação e outras questões relacionadas ao registro de marcas e o novo tratado internacional, vigente no Brasil, desde outubro de 2019. Renata Lisboa, advogada especializada em Propriedade Intelectual e recentemente eleita membro do Conselho Diretor da ABPI também participa do episódio.
A Lei de Franquias, de 1994, será alterada pelo PL 219, de 2015, aprovado no último mês de novembro, e que aguarda agora sanção presidencial. Nesse episódio do ABPI Cast, o presidente da Associação Brasileira de Franchising (ABF), André Friedheim, fala da importância desse momento e da batalha da ABF para modernização da Lei, que melhora o relacionamento entre franqueador e franqueado e profissionalizará, ainda mais, a questão das franquias no Brasil. Participa da entrevista a advogada Candida Caffé, coordenadora da Comissão de Transferência de Tecnologia e Franquias da ABPI.
Nessa edição do ABPI Cast a entrevista é com Maria Eugênia Gallotti, gerente do projeto Protocolo de Madri, do INPI. Ela fala da importância do tratado internacional, que entrou em vigor no Brasil no último dia 2 de outubro, e tem como objetivo simplificar e reduzir custos dos procedimentos para registro de uma marca em países estrangeiros. Também participa da nova edição Renata Lisboa, advogada especializada em Propriedade Intelectual e recentemente eleita membro do Conselho Diretor da ABPI.
O ABPI Cast recebe Caroline Somesom Tauk, juíza federal, mestre em Direito Público pela UERJ e Visiting Scholar em Columbia Law School. Nesse programa falaremos, principalmente, da valorização do diálogo entre os sujeitos processuais, partes, advogados e juízes no saneamento do processo. O tema também foi abordado no artigo de Caroline Tauk, “O Saneamento Cooperativo e seus Impactos nas Ações da Propriedade Industrial”, publicado na edição 155 da Revista da ABPI. Participa ainda do programa, Renata Lisboa, sócia de Araripe & Associados, advogada especializada em Propriedade Intelectual, com atuação no contencioso judicial, co-autora da obra Novo Código de Processo Civil Anotado – organizada por Rafael Corte Melo e Romulo Ponticelli Giorgi Jr. Renata foi eleita, recentemente, membro do conselho diretor da ABPI.
A operação montada para resolver o problema do backlog de patentes e dar ao INPI “eficiência de uma empresa privada” é uma das principais frentes de batalha da nova gestão do INPI, mas não é a única. A falta de autonomia financeira e administrativa do órgão, por sinal uma antiga reivindicação da ABPI, está em estudo no Ministério da Economia, e a boa notícia é que pode ser aprovada no ano que vem. Entenda tudo nessa entrevista com Claudio furtado, presidente do INPI.
Piers Ricketts – Chair AHSN Network and Chief Executive Eastern AHSN Dr Sam Roberts – Chief Executive Officer of the Accelerated Access Collaborative (AAC), Director of Innovation and Life Sciences, NHS England and NHS Improvement Mike Thompson – Chief Executive, ABPI
In this episode we welcome two titans of Maltese Podiatry who talk to us about studying in Malta (which given the climate and the low fees seems like a very attractive opportunity) and showcase some of the huge research output they have been involved in concerning the diabetic foot (and why you may want to think about toe pressures rather than the ABPI, and also think about treating yourself to a thermal camera). Loads of great slides throughout this one so will work better as a video than a podcast! Let us know if the thought of a Masters degree from the University of Malta intrigues you and you want Cynthia or Alfred's contact details.
Today in FirstWord:
BARCELONA—Accelerated partial breast irradiation (ABPI) brachytherapy completed in a single week gave at least as good efficacy and safety as other radiotherapy protocols after breast-conserving therapy (BCS) for patients with low-risk breast cancer and brought advantages in terms of symptoms …Rebekka Schäfer AJO INTERVIEW Production MASTER
Today in FirstWord:
Today in FirstWord:
Greg McMahon shows James Blackwell how to find and examine the aorta and peripheral pulses by hand and using the Doppler probe. Have a look at our podcast on ABPI as well and you'll pass that OSCE station with no problem at all! Greg McMahon is a consultant vascular surgeon and James Blackwell is a research fellow in Surgery at the Royal Derby Hospital, UK
ABPI is not a credit card interest rate, but just about the most important measurement you can make in vascular surgery.Find out what it is, what it means, who not to do it on, and a video on how to perform it quickly and efficiently using our point of view technique (like you're really there!) with James Blackwell (research fellow in surgery) and Greg McMahon (consultant in Vascular Surgery, Royal Derby Hospital, UK). This comes up in OSCEs a lot and so is essential knowledge for exams, both undergraduate and postgraduate, and you never know, might actually be useful when you're treating patients! If you just want to watch how to do the ABPI and not hear the what and why, skip to 6:30 in the video
© 2020-2025 Ivy Podcast Discovery LLC
